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The industrial production of proteins in bacteria has found its limits due to the size 
and requirements of post-translational folding of many proteins. However, bacteria are 
still a preferred expression host and various tools are applied to broaden the expression 
spectrum of these microorganisms. We investigated methods to decrease costs and 
improve protein expression in Escherichia coli and applied tools such as genetic 
engineering, change of promotor and signal peptides, and aiding disulphide bond 
formation. Here we examined the ability of Escherichia coli strain MC4100 encoding 
the TatABC protein secretion pathway of Agrobacterium tumefaciens to export 
complex proteins into the periplasm. We have shown that the mutant strain can export 
native Tat proteins but rejects non-native proteins of biopharmaceutical interest which 
are exported over Tat in Escherichia coli wildtype. Furthermore, we examined a 
sodium nitrate inducible promoter on its expression strength and periplasmic export, 
and we conducted research into the expression and export to the periplasm of the novel 
biodegrading enzyme PETase. Additionally, we show that the narG-CC promoter is 
capable of high-level protein expression of GFP but does not facilitate periplasmic 
expression of hGH and an scFv. Furthermore, we show that PETase can be exported 
into the periplasm by the Sec pathway but not the Tat pathway. The combined research 
shows that Escherichia coli is still a key player in the production of recombinant 
proteins and that proteins that require cytoplasmic post-translational folding can be 
exported under the correct circumstances, although finding the best tools to improve 
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Å Ångströms  
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1.1. Biotechnology Industry 
We understand the term biotechnology as “the use of living organism/s or their 
product/s to modify or improve human health and human environment”. With this 
definition, we recognise that biotechnology is as old as human history and an example 
for early use of biotechnology is fermentation (Verma et al., 2011). The oldest 
fermentation products that have been found date back to 7000 to 6000 BCE and it is a 
fermented drink made out of fruit, honey and rice found in China (McGovern et al., 
2004). It took many centuries from accidental biotechnology to modern/ directed 
biotechnology. The construction of bacterial plasmids and DNA cloning in 1973 has 
paved the path of genetic engineering and modern biotechnology (Cohen et al., 1973). 
The origins of biotechnology as we know it nowadays in relation to industry are 
strongly connected with the history and discovery of insulin. Human insulin is the first 
recombinant protein drug to have been licensed. The so called Humulin, a recombinant 
human insulin, was also the first drug produced using recombinant DNA. Humulin 
was approved by the US Food and Drug Administration (FDA) in 1982. Insulin is 
expressed from a small, double-strand DNA ring called a plasmid which is inserted in 
the bacterial cell. Insulin is composed of two peptide chains, insulin A and insulin B 
chain, which are linked together by two disulphide bonds. At the time, insulin was 
expressed in a two-plasmid system. The two peptide chains were purified and then 
disulphide bond formation was promoted to produce bioactive insulin (Johnson, 1983; 
Baeshen et al., 2014). Insulin accumulates within the cell and after the growth process 
2 
 
the bacteria are broken open to purify the protein (Nilsson et al., 1996; Baeshen et al., 
2014). 
Before insulin was produced in E. coli, insulin was purified from pancreatic tissue of 
cows and pigs (Sanger, 1958; Vecchio et al., 2018). At that time, the quality of insulin 
was variable and the yields were low (Lens and Evertzen, 1952). Additionally, 
challenges were provided by the transport of the pancreatic tissue which had to be kept 
frozen. Otherwise, the pancreatic tissue would no longer have been suitable for 
purification. Up until today, E. coli is used as host for the expression of insulin using 
expression plasmids and purification from the bacterial cells. In the early 90s yields 
of 100g dry cell weight per litre could be achieved which was a major success and is 
still applicable today (Yee and Blanch, 1992; Lee, 1996; Yamanè and Shimizu, 2005). 
The landscape of products changed towards more complex molecules like antibodies 
with complex folding requirements in the mid-90s. E. coli was the preferred host for 
biopharmaceutical production because of its economic ease of culture and cost-
effectiveness, but could not fulfil the folding requirements of the new substrates 
(Swartz, 2001). Nowadays, E. coli is still a key player for protein production with 
about 24% of the approved therapeutics being produced in this host organism 
(Baeshen et al., 2014; Mohamed N. Baeshen, 2014). Examples for those therapeutics 
are various interferons and cancer drugs such as Endostatin, Tasonermin, and 
Filgrastim (Sanchez-Garcia et al., 2016). However, mammalian cell based protein 
production dominates the market, see Figure 1, as mammalian cells are able to express 
complex proteins with several disulphide bonds and sizes over 150 kDa, such as 
antibodies (Ranade, 2010). In 2010 about 40% of approved therapeutics were 
glycoproteins (proteins requiring glycosylation to be functional) (Lingg et al., 2012). 
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The oligosaccharide structures differ depending on the host machineries of 
glycosyltransferases and the culture conditions. Therefore, the same amino acid 
sequence can have different glycoforms (Higgins, 2010). The glycan profile of 
proteins expressed in many mammalian cells is similar to that of the native human 
proteins which makes mammalian cells a preferred system. 
In comparison, in 2011 30% of biopharmaceuticals, typically defined as a drug 
produced from a biological source, were produced in E. coli and only 39% in 
mammalian cells (Waegeman and Soetaert, 2011). 
 
Figure 1: Cell lines used for pharmaceutical production. Here presented are the estimated 
percentages of cell lines used for biopharmaceutical production, based on numbers from 2014. 
Mammalian cell lines are dominating the market with about 56% of biopharmaceuticals 
produced in mammalian cell lines, most commonly used are Chinese Hamster Ovary (CHO) 




Compared to mammalian host systems E. coli is a desirable expression system because 
of its rapid growth rate, capability of high-level expression, and cost-effectiveness 
(Waegeman and Soetaert, 2011). An initial challenge to overcome when using 
mammalian cells was that the cells prefer to be adhered to a surface while E. coli can 
grow in suspension. However, nowadays most processes use cell lines growing in 
suspension and only certain mammalian some used cell lines are anchorage-dependent 
(Flickinger et al., 2010; Bielser et al., 2018). Additionally, E.coli can be grown at 
various different temperatures and is, compared to mammalian cell cultures, flexible 
towards temperature and pH changes within the culture (Werner and Noé, 1993; 
Bielser et al., 2018). Therefore, the fermenter systems used have less technical 
requirements, are cheaper, and allow a higher cell density. The cost of recombinant 
protein production in E. coli can be further decreased with targeting the desired protein 
into the growth medium or the periplasm to simplify purification processes and 
therefore reduce downstream costs (Quax, 1997; Burdette et al., 2018). 
Many systems have been developed to perform genetic manipulations to optimize E. 
coli further for higher yields and optimized protein expression (Lee et al., 2009; 
Thomason et al., 2014) and our understanding of protein folding and folding factors 
has improved (Swartz, 2001). E. coli has limitations for protein production such as 
limits in post-translational folding. The folding pathway in E. coli will be described at 
a later stage. These limits are a major factor driving in the expansion of mammalian 
cell production systems. Protein yields can be low even for protein expression 
optimized bacterial strains, plasmids and promoters (short DNA sequence that 
regulates expression of a plasmid) but with genetic manipulations the so far known 
limits can be changed. Scientists are continuously on the search for new tools for the 
biotech industry to overcome current limitations and optimise protein production 
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processes for new targets. In industry most proteins are produced in a fermentation 
process. Fermentation has been defined as ‘a chemical process by which molecules 
are broken down anaerobically by yeast or bacteria’ (Fuchs and Schlegel, 2006). 
Fermentation can increase the yields, optimise conditions and in some cases can reach 
high-cell-density cultures (Luli and Strohl, 1990). One form of fermentation is fed-
batch fermentation where essential substrates are supplied to prevent starvation of 
cells or overfeeding throughout the fermentation process (Money, 2016). Some 
substrates such as 2,3-butanediol are not suited for a batch process due to an initial 
high substrate concentration which leads to a substrate inhibition and low culture 
yields (Sabra et al., 2011). Increasing substrate availability has the benefit, that 
productivity of the cells can be maintained over a longer period of time and substrate 
inhibition can be prevented (Sabra et al., 2011; Srivastava and Gupta, 2011). 
To improve protein production for biotechnological purposes one can choose several 
strategies. Aspects that are commonly changed to improve protein expression are the 
plasmids and the hosts (Waegeman and Soetaert, 2011). Changes on the plasmid can 
be the signal peptide targeting the protein to a specific pathway or the promoter used 
in the expression cassette. Another method can be a genetic engineering of the host 
strain with changing aspects on the genome (Makrides, 1996). To develop a further 
understanding of recombinant protein production and the pathways that can be 






1.2. Protein export in bacteria 
An essential function of prokaryotic cells is the export of proteins through the 
cytoplasmic membrane as all major polypeptides are synthesised in the cytoplasm 
(Clark and Pazdernik, 2013). The translocation has to maintain the structural integrity 
or function of the cytoplasmic membrane (CM) whilst exporting the protein. This can 
happen via several pathways. There have been in total sixteen different pathways 
found in bacteria (Economou et al., 2006). Some of those pathways only occur in 
either Gram-negative or Gram-positive prokaryotes (Economou et al., 2006; Green 
and Mecsas, 2015). The most common pathways for the transport of soluble proteins, 
both found in Gram-negative and Gram-positive bacteria, are the general secretory 
pathway (Sec) and the Twin-Arginine Translocase (Tat) pathway (Green and Mecsas, 
2015). A third pathway, the co-translational Signal Recognition Particle (SRP)-
mediated pathway is more commonly used for the insertion of membrane proteins, 
although SRP is also used for the export of some soluble proteins. The most important 
difference between the Sec and the Tat those two pathways to point out is that the Sec 
pathway translocates unfolded proteins while and the Tat pathway translocates 
proteins that have been folded in the cytoplasm (Green and Mecsas, 2015). 
Both pathways have been identified with minor variations in archaea, bacteria, and 
eukarya (Robinson and Bolhuis, 2004; Papanikou, Karamanou and Economou, 2007). 
Tat is found in the thylakoids of plants and green algae and in the plasma membranes 
of bacteria and archaea. The Sec pathway in E. coli exports the majority of proteins 
(Natale, Brüser and Driessen, 2008) and the Tat pathway exports about 30 native 
proteins, some of which are crucial for cell division and cell vitality (Palmer, Sargent 
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and Berks, 2010).The current work focusses on the exploitation of the Tat pathway for 
the secretion of fully folded proteins. 
 
1.3. Protein folding in bacteria 
The majority of proteins need to be folded into a three-dimensional structure which is 
an error prone process because it relies on the interaction of amino acids far apart in 
the sequence (Balchin, Hayer-Hartl and Hartl, 2016). Furthermore, misfolded proteins 
can accumulate and can, because of their exposed hydrophobic amino-acid residues, 
form toxic aggregates (Kim et al., 2013). To avoid the accumulation of misfolded 
proteins, cellular pathways have evolved to assist in protein folding and refolding, and 
to degrade misfolded proteins that are refractile to refolding (Hartl, 2017). The 
network that maintains proteins in correct concentration is called protein homeostasis 
or proteostasis network (Powers, Powers and Gierasch, 2012) Chaperones (proteins 
that interact with other proteins to stabilise or aid to acquire its functionally active 
conformation) are responsible for maintaining proteostasis (Hartl, Bracher and Hayer-
Hartl, 2011). A variety of chaperones have been identified such as foldase chaperones 
(mediating folding), unfoldases (correcting folding mistakes), Sec-avoidance 
chaperones (preventing targeting to the Sec pathway), proofreading chaperones 
(suppressing further transport till folding is finished), and chaperones that protect the 






1.3.1. Trigger factor 
Several chaperones are involved in maintaining proteostasis. One of these chaperones 
is trigger factor (TF) which binds to the ribosome exit tunnel and initiates folding of 
newly synthesized proteins (Merz et al., 2008). TF interacts with the unfolded protein 
which is passing through the interior of TF and then assists the folding of the nascent 
chain. The contact to TF is lost when the nascent chain changes its conformation due 
to folding and the hydrophobic regions of the nascent chain are buried within the 
nascent polypeptide(Merz et al., 2008; Hartl, Bracher and Hayer-Hartl, 2011). The 
release from TF is ATP independent and transfers proteins to the downstream 
chaperones. Such a downstream chaperone is Hsp70 (Morán Luengo, Mayer and 
Rüdiger, 2019). 
 
1.3.2. The Hsp70 chaperone system of E. coli 
The heat shock protein 70 (Hsp70) has been found in many organisms, from bacteria 
to human. Genome sequencing has shown that many organisms encode multiple 
members of the Hsp70 family. In E. coli three members of the Hsp70 family have been 
found (Genevaux, Georgopoulos and Kelley, 2007; Powers, Powers and Gierasch, 
2012). One of the Hsp70 chaperones in E. coli is DnaK which is involved in the DnaK-
DnaJ-GrpE cascade. The DnaK machinery is usually referred to as KJE and is the best 
studied Hsp70 system in E. coli. This chaperone machine consists of DnaK, the 
cochaperone DnaJ (Hsp40), and the nucleotide exchange factor GrpE. (Genevaux, 
Georgopoulos and Kelley, 2007; Imamoglu et al., 2020). 
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The role of the KJE system is to bind misfolded proteins and unfold them (Powers, 
Powers and Gierasch, 2012). DnaK can be in in a high and low affinity state and is in 
an open state when ATP binds to the nucleotide-binding domain (Powers, Powers and 
Gierasch, 2012; Imamoglu et al., 2020). A substrate can bind directly to DnaK or it 
can bind to the cochaperone DnaJ which is transferring the substrate to DnaK. When 
ATP is hydrolysed, DnaK undergoes a conformational change, causing the bound 
substrate to change conformation (Powers, Powers and Gierasch, 2012). However, the 
process how DnaK folds the substrate is not yet understood (Imamoglu et al., 2020). 
 
1.3.3. Chaperonin system GroEl-GroES 
Another downstream chaperone system is the chaperonin GroEL-GroEs in the 
bacterial cytosol (Kim et al., 2013). Chaperonins enclose the substrate for folding 
which has the benefit that this protects the substrate of aggregation or rebinding to 
upstream chaperones (Hartl, Bracher and Hayer-Hartl, 2011). The substrate binds to 
GroEL which has hydrophobic amino acid residues facilitating the binding. In the next 
step, ATP binds to GroEL triggering a conformational change which allows GroES to 
bind to the substrate-GroEL complex. The binding of GroES leads to the enclosure of 
the substrate in the chaperonin cavity (Clare et al., 2012). Proteins up to 60 kDa can 
be encapsulated in this process (Tang et al., 2006). The enclosure takes approximately 
10 seconds, then GroES dissociates from the complex, by ATP binding, and the folded 
protein leaves GroEL. If the protein is incompletely folded it gets recaptures for 




1.3.4. Protein degradation 
ATP dependent proteases (AAA+) are responsible for degradation of proteins. Five 
different types of AAA+ proteases are found in E. coli. These are ClpXP, ClpAP, 
HslUV, Lon and FtsH (Sauer and Baker, 2011; Nyquist and Martin, 2014). These 
proteases have their oligomeric barrel like complex in common. The complex contains 
subunits with two functional domains, the ATPase and the proteoase domain (Bittner, 
Arends and Narberhaus, 2017). When a substrate binds to the AAA+ protease, the 
substrate is unfolded, translocated, and finally degraded. Binding can occur in a direct 
manner or indirect mediated by adaptor proteins. The next step is ATP-dependent. The 
ATPase domain of the AAA+ protease unfolds the substrate and translocate the 
substrate into the proteolytic chamber of the protease domain. The final step, the 
protease domain degrades the substrate in approximately 5 to 25 amino acid long 
peptide fragments (Gur, Biran and Ron, 2011; Gur, Ottofueling and Dougan, 2013). 
1.4. The general secretory pathway (Sec) 
The Sec pathway is the best understood pathway in bacteria and all the genes involved 
have been identified (Driessen and Nouwen, 2008). The majority of exported proteins 
in E. coli are translocated by the Sec pathway (Pugsley, 1993; Papanikou, Karamanou 
and Economou, 2007). Proteins are transported in an unfolded state across the CM and 
are called pre-proteins because of the removable amino (N)- terminal signal peptide 
which is cleaved off after translocation. The Sec pathway can be found in different 
domains of life and some of its components, such as SecY, are also present like the 
secY gene can be found in archaea and eubacteria. The Sec61 complex, built by 
Sec61α, Sec61β, and Sec61γ, is found in eukaryotes (Cao and Saier, 2003). The Sec 
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pathway is essential for cell viability in all organisms(Berg et al., 2004; Du Plessis, 
Nouwen and Driessen, 2011). 
 
1.4.1. Sec dependent insertion of membrane proteins 
The Sec translocon in most bacteria is built up by eight different proteins embedded 
into the cytoplasmic membrane (Nouwen et al., 2005). Those proteins can be 
classified as essential for translocation or essential for the efficiency of translocation, 
and the proteins include integral membrane proteins, protein export chaperone (SecB) 
and ATPase translocation motor (SecA) (Pogliano and Beckwith, 1994; Sachelaru et 
al., 2017). Three of the integral membrane proteins that are essential for translocation 
are the protein translocase subunit SecY, the protein translocase subunit SecE, and the 
protein-export membrane unit SecG. Those three proteins together form SecYEG 
complex (Brundage et al., 1990). The largest component of the SecYEG complex is 
SecY with 48 kDa and 10 transmembrane α-helical segments (TMS), followed by 
SecE with 14 kDa and 3 TMS, and SecG the smallest membrane protein of the 
complex has a mass of 12 kDa and 2 TMSs as schematically presented in Figure 2 






Figure 2: Schematic diagram of the transmembrane structure of SecY, SecE, and 
SecG. SecY is the largest component with 10 transmembrane segments. SecE has three 
transmembrane segments, and SecG is the smallest protein unit with two TMSs. 
 
Additional components of the translocon are the protein translocase subunit SecA and 
the membrane protein insertase YidC. YidC is 61 kDa and SecA is even larger with 
102 kDa. SecA, which has not been found in archaea, is functions as an ATPase and 
functions as the Sec pathway translocase motor (Oliver, 1993; Müller et al., 
2001).YidC, SecA, and the SecYEG complex are understood to be the main 
components for the functionality of the Sec pathway (Cao and Saier, 2003). SecA has 
the ability to interact with all components of the translocation system and is involved 
in the initial binding as well as translocation across the structure (Oliver, 1993) and 
YidC is involved in membrane biogenesis and further assists the transfer of proteins 
by interacting with the surface of the lateral gate of SecY (Sachelaru et al., 2013, 
2017). 
The essential components of the E. coli Sec pathway are presented in Figure 3. Also 
shown in Figure 3 is the SecDF (yajC) complex built by the protein translocase subunit 
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SecD, the protein translocase subunit SecF, and the Sec translocon accessory complex 
subunit yajC. SecD and SecF have large periplasmic domains that make up about one 
third of their size (Pogliano and Beckwith, 1994; Nouwen et al., 2005). The SecDF 
(yajC) complex does not occur in all prokaryotes and has not been found in eukaryotes. 
Furthermore, the complex is not essential for the functionality of Sec related export 
(Tseng et al., 1999). However, SecDF is essential for efficient export by the Sec 
pathway. In E. coli, the deletion of secD and secF, and therefore the SecDF (yajC) 
complex, has resulted in a 10-fold decrease of exported protein compared to wildtype 
(WT) cells (Pogliano and Beckwith, 1994). The detailed function of the SecDF(yajC) 
complex remains unclear, however, it has been proposed that SecDF(yajC) is 
regulating the activity of SecA and SecG (Tsukazaki, 2018). Another working model 
suggests that SecDF interacts with an unfolded protein and is using the PMF to drive 
the forward movement of the protein and prevent backward movements (Tsukazaki 





The export of proteins to the periplasm requires signal peptides at the N-terminus of 
the protein to be successfully translocated by the Sec pathway and these are 
subsequently removed to generate the mature protein (Makrides, 1996). 
 
1.4.2. Sec-specific signal peptides 
The so far known signal peptides targeting proteins to the Sec pathway do not share 
sequence similarities. However, they share similarities in their overall structure. They 
have a positively charged n-region, a hydrophobic h-region of approximately ten 
amino acids, and the c-region contains a consensus cleavage motif of A-X-A as shown 
in Figure 4 (Dalbey and Kuhn, 2000; Rusch and Kendall, 2007). The Sec-specific 
signal sequences are typically about 20 amino acids long (Papanikou, Karamanou and 
Economou, 2007; Green and Mecsas, 2015). 
 
Figure 3: Structure of the Sec pathway. The Sec pathway is located in the cytoplasmic 
membrane (CM). The major parts are the protein-conducting channel SecYEG (blue), a 
cytoplasmic based motor domain SecA (green), and the two heterotrimeric complexes 
SecDF (orange) and YidC (red). SecYEG and YidC support pre-protein insertion. The pre-





Figure 4: Schematic presentation of the Sec signal peptide motif. Identified Sec specific 
signal peptides have a positively charged n-region, a hydrophobic h-region and share the 
A-X-A motif in the c-region. 
 
Proteins with well characterised Sec signal peptides are for example OmpA (Movva, 
Nakamura and Inouye, 1980) and PhoA (Kikuchi et al., 1981; Inouye et al., 1982; 
Sjöström et al., 1987). OmpA is an outer membrane protein with an N-terminal signal 
peptide which has been known since 1978 when its sequence was first determined 
(Endermann, Hindenach and Henning, 1978; Movva, Nakamuran and Inouye, 1980). 
The signal peptide together with the mature protein build the precursor protein which 
are recognised either by the signal recognition particle (SRP) or the SecB chaperone. 
Some proteins, such as OmpA, are SecB dependent whereas others like integral 
membrane proteins are targeted by SRP (Lee and Bernstein, 2001). 
 
1.4.3. Sec specific translocation 
The Sec translocon is located in the cytoplasmic membrane and the process can be 
divided into three steps. In the first step, pre-proteins are targeted to the Sec pathway 
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and are recognised either by the SRP (Figure 5A, targeting route 1) or the SecB 
chaperone (Figure 5A, targeting route 2). Sometimes the two different recognition 
ways are differentiated into two different Sec-related pathways referred to as the SRP 
pathway and the Sec pathway (Luirink and Sinning, 2004; Lee et al., 2016). 
SecY, SecE and SecG build the protein-conducting channel (SecYEG) and has a 
cytoplasmic based motor domain (SecA). The SecYEG complex is a narrow protein-
conducting channel with a size of 5 to 8 Å and contains a SecA specific binding 
domain (Berg et al., 2004). When the pre-protein is targeted to the membrane by the 
SecB chaperone, SecB binds to SecA. SecYEG can either interact with SRP for co-
translation of mostly highly hydrophobic, integral membranes for lipid-phase 
integration or it interacts with the SecB/ SecA/ preprotein complex over the SecA 
binding domain for complete translation of less hydrophobic proteins as shown in 
Figure 5A (Randall and Hardy, 2002; Holland, 2004; Ito and Mori, 2009; Sachelaru 
et al., 2017). SecA is known to drive translocation using ATP for its conformation 
changes during translocation and different models have been proposed for the 
translocation process itself (Cranford-Smith and Huber, 2018; Komarudin and 
Driessen, 2019). 
SecYEG is also flanked by SecDF and YidC. SecDF and YidC support protein 
insertion and YidC interacts with the lateral gate of SecY in relation to the substrate 
availability. For SecA to work as a motor domain ATP binding is required and whilst 
undergoing conformational transition, SecA interacts with SecY (Kostakioti et al., 
2005). The third step of the Sec translocation is the release and maturation of the pre-
protein (see Figure 5B). Throughout the process the hydrophilic, positively charged 
N-terminal region remains membrane located. The pre-protein is converted into a 
mature protein since the signal peptide, having targeted the pre-protein to the Sec 
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pathway, is cleaved by the signal peptidase. In a final step, the protein is folded into 
its native configuration on the trans side of the membrane, sometimes with the aid of 




Figure 5: Sec-dependent translocation. A shows the two different ways pre-proteins 
(black line) can be targeted to the Sec pathway by the signal-recognition particle (SRP) 
(dark red) or the SecB chaperone (light red). The pathway in the image labelled with 1, is 
mediated by SRP and is used for co-translation. The pathway labelled with 2 is SecB 
mediated targeting used for co- and post-translational insertion of membrane proteins. This 
targeting is driven by an N-terminal signal sequence. In B, the protein gets pushed through 
the membrane driven by the SecA ATPase which is step 2 in the secretory process. Not 







1.4.4. Disulphide bond formation in the periplasm 
There are two systems that are responsible for periplasmic protein folding (Bardwell, 
McGovern and Beckwith, 1991; Miot and Betton, 2004). The first catalysts are the 
Dsb proteins, which form disulphide bonds and the second are peptidyl-prolyl 
isomerases (PPIase). 
To create a disulphide bond with Dsb proteins, DsbA donates its own disulphide bond. 
In the first step, DsbA reacts with the target protein and creates an unstable mixed 
disulphide. In a second step, the mixed disulphide is targeted by another thiol group 
of the target protein and replaces the mixed the disulphide (Kadokura, Katzen and 
Beckwith, 2003; Nakamoto and Bardwell, 2004). 
PPIases assists protein folding by catalysing a cis-trans isomerization of proline 
residue. The four identified PPIases are SurA, FkpA PpiA and PpiD (Mogensen and 
Otzen, 2005). Whilst it is understood which family of PPiases they belong to, SurA, 
FkpA, PpiA and PpiD do not appear to be essential for bacteria and their cellular role 
has not been entirely understood (Miot and Betton, 2004). 
Furthermore, quality control proteases, such as the Deg protease family, are involved 
in the quality control process. Deg (in plant or bacteria) or HtrA (in mammalian cells) 
proteases are found in almost every organism (Kieselbach and Funk, 2003). In E. coli 
DegP is involved in degrading irreversibly damaged proteins and as chaperone 
assisting in the refolding of denatured or misfolded proteins (Schuhmann and 
Adamska, 2012). 
An interesting example for successful expression with periplasmic folding in E. coli 
is the expression of tissue plasminogen activator (tPA) which requires 17 disulphide 
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bonds for its active state. The research group, overexpressed DsbA and DsbC to 
promote periplasmic disulphide bond formation. Through the overexpression they 
could improve the protein yield of correctly folded protein by 25% (Qiu, Swartz and 
Georgiou, 1998). 
If the proteins are misfolded, they will be degraded by proteases (Strauch, Johnson 
and Beckwith, 1989). 
 
1.5. The Twin-Arginine Translocase (Tat) pathway 
The second major export system is the Tat system which is found in most bacteria 
(e.g. Gram-positive bacteria such as B. subtilis and S. aureus and Gram-negative 
bacteria such as E. coli) and in the chloroplasts of higher plants and algae (Sargent, 
2007; Patel, Smith and Robinson, 2014). The Tat pathway transports proteins in a 
folded state and could therefore be capable of transporting more complex 
biopharmaceuticals that require cofactor insertion and disulphide bond formation. In 
previous experiments, Tat has been exporting successfully single chain variable 
fragment (scFv) and human growth hormone (hGH) (Browning et al., 2017). So far 
the protein yields have been too low for commercial use and various efforts have been 
done to improve Tat export (Robinson et al., 2011). However, it has been shown that 
the Tat pathway transports correctly folded proteins and heterologous proteins into the 
periplasm, suggesting that it has potential as a powerful tool for recombinant protein 
production (Matos et al., 2014; Alanen et al., 2015). Tat specific proofreading is 





In extremophile bacteria (e. g. Haloferax volcanii and Natrialba magadii) 
approximately 50% of the proteins are transported over the Tat pathway. In contrast, 
in E. coli only about 30 proteins in total are transported over the Tat machinery (Rose 
et al., 2002; Dilks et al., 2003; Ghosh et al., 2019). When the Tat pathway in E. coli 
is deleted the bacterium is still viable. However, the cells are unable to divide and a 
filamentous chain phenotype occurs due to the lack of a cell wall amidase required for 
daughter cell separation (Stanley, Findlay and Berks, 2001; Bernhardt and De Boer, 
2003; Ize et al., 2003). Interestingly, an overexpression of the tat genes does not lead 
to a change in phenotype and the cells are capable of expressing high concentrations 
of recombinant protein even throughout fermentation processes (Matos et al., 2012). 
Native Tat substrates range in size from 30 kDa up to 150 kDa and the pathway has 
been named after the Arg-Arg motif found near the N-terminus of the signal peptide 
(Delisa, Tullman and Georgiou, 2003; Palmer and Berks, 2012; Berks, Lea and 
Stansfeld, 2014). The Arg-Arg motif is found in almost all signal peptides targeting 
the proteins to the Tat pathway and some examples are shown in Table 1 on page 26. 
 
1.5.1. Tat membrane proteins 
Many Tat systems utilise three membrane proteins, TatA, TatB, and TatC (Müller and 
Klösgen, 2005; Kanehisa Laboratories, 2010). The three integral membrane proteins, 
and additionally TatD, are encoded by the tatABCD operon which is shown in Figure 
6. tatD is not involved in the Tat pathway and encodes a DNase (Wexler et al., 2000). 
The E. coli genome additionally contains a tatE gene which is found further 




Figure 6: E. coli tatABCD. tatABCD operon is flanked by the genes ubiB and rfaH genes. 
TatE is not shown here as it is located elsewhere in the genome. 
 
TatA is 89 amino acids long with a mass of 9.6 kDa, TatB is a 171 amino acid long 
protein (18.5 kDa), and TatC consists of 258 amino acids with a molecular weight of 
28.9 kDa (Patel, Smith and Robinson, 2014). TatA and TatB share about 20% 
sequence similarity but have distinct functions (Lee et al., 2002; Hicks et al., 2003). 
TatC, as the largest membrane protein in the complex, traverses the membrane six 
times. TatA and TatB span the membrane once and each has an unstructured C-
terminal region and a α-helix at their N-terminus. C- and N-terminal of all three 
proteins are located in the cytoplasm. Figure 7 shows the topography of TatA, TatB, 
and TatC in the cytoplasmic membrane. TatE is a paralogue for TatA and shares 57% 
sequence similarity and according to Eimer et al. TatA and TatE share a ‘striking 
functional and structural similarity’(Sargent et al., 1998; Eimer et al., 2015). TatE 
seems to be E. coli specific as this gene could not be found in many Gram-negative 
bacteria. (Berks, Lea and Stansfeld, 2014; Patel, Smith and Robinson, 2014) It has 
been shown that TatE can fulfil the role of TatA in ∆tatA mutant strains. tatE is 
expressed in such low levels that only basic functions can be maintained (Robinson 





Figure 7: Topography of the proteins involved in the E. coli Tat pathway. Typically, 
three integral membrane proteins are encoded by the tatABC operon. TatA is 89 amino 
acids long, TatB is a 171 amino acid protein and shares a 20% similarity with TatA. In 
contrast, TatC consists of 258 amino acids and traverses the membrane 6 times. Both, C- 
and N-termini are located in the cytoplasm. 
 
TatA, TatB, and TatC are expressed in different amounts. Their ratio is approximately 
30:1:0.4 for TatA:TatB:TatC (Jack et al., 2001; Berks, Palmer and Sargent, 2003). 
Jack et al. report that TatA is being expressed the most and TatB is being expressed 
26-fold lower than TatA (Jack et al., 2001). 
Depending on whether the bacteria is Gram-positive or Gram-negative, differences 
can be found in the Tat system. In Gram-negative bacteria TatA, TatB, and TatC build 
a complex which is essential for the functionality of the Tat pathway. Gram-positive 
bacteria with a high GC-content and plants contain a TatABC based Tat system (Dilks 
et al., 2003; Joshi et al., 2010). However, in gram-positive bacteria with a low-GC-
content in the genome and in archaea often only TatAC subunits exist (Barnett et al., 
2009; Palmer and Berks, 2012). The Gram-positive bacterium Bacillus subtilis (low-
GC-content genome) uses two Tat systems which are both build of TatAC subunits 
24 
 
(TatAdCd and TatAyCy) (Barnett et al., 2009; Goosens, Monteferrante and Van Dijl, 
2014). 
 
1.5.2. Tat specific signal peptides 
As previously noted, the Tat specific signal peptides all contain a twin-arginine motif 
(SRRxFLK) near the N-terminus which gave the pathway its name (Hinsley et al., 
2001; Sargent, 2007). After the RR follows usually a polar amino acid (Müller and 
Klösgen, 2005). Furthermore, the signal peptides possess a positively charged n-
region and a hydrophobic h-region like Sec signal peptides (Natale, Brüser and 
Driessen, 2008). The main difference between Tat and Sec signal peptides is that the 
former are generally longer. On average Tat signal peptides are about 24 to 38 amino 
acids long compared to typically 20 amino acid long signal peptides targeting the Sec 
pathway (Patel, Smith and Robinson, 2014). Also, the Tat signal peptide h-region is 
less hydrophobic compared to the Sec signal peptide h-regions, shown in Figure 8 
(Cristóbal et al., 1999). Furthermore, some signal peptides contain at the c-region an 
increased amount of positive charged amino acids which has been identified as a Sec-
avoidance motif (Blaudeck et al., 2003). For E. coli 22 to 34 Tat targeting signal 
peptides have been predicted. Some of those target the proteins to the Tat pathway and 
some signal peptides are promiscuous and can mediate export to Tat and Sec. Such a 
promiscuous signal peptide is AmiC (Blaudeck et al., 2003; Dilks et al., 2003; 
Tullman-Ercek et al., 2007). It is unclear why some Tat signal peptides are 
‘ambiguous’ and whether the signal peptides have an influence on the folding of the 
mature protein is unclear. This might be possible since Sec-dependent proteins tend to 




Figure 8: Comparison of the general motif of signal peptides targeting to the Sec and 
the Tat pathway. Tat signal peptides are in comparison 4 to 18 amino acids longer, their 
h-region is less hydrophobic, they also contain a twin-arginine motif in the n-region and a 
sec avoidance motif in the c-region. Adapted from Cristóbal et al., 1999. 
 
The signal peptides used in this study are AmiC, TorA, PhoD, and HyaA. Their signal 
sequence and shared motif is shown in Table 1. HyaA, TorA, and PhoD are Tat 
unambiguous signal peptides and AmiC, whilst being a signal peptide for the Tat 









Table 1: Representation of the twin-arginine motif of the signal peptides used in this 
study. The Tat signal peptides share a common structure with a hydrophobic h-region and a 
positively charged n-region. The Arg-Arg motif is underlined.  














AmiC MSGSNTAISRRRLLQ GAGAMWLLSV SQVSLA 
 
The AmiC signal peptide was shown to be a Tat signal peptide in 2003. GFP cannot 
be exported in a functional state via the Sec pathway. However, when fused to AmiC, 
GFP gets exported to the periplasm (Bernhardt and De Boer, 2003). Trimethylamine 
N-oxide (TMAO) reductase (TorA) has been shown to have a N-terminal Tat signal 
peptide (Barrett et al., 2003; Palmer, Berks and Sargent, 2010; Browning et al., 2017). 
AmiC and TorA have been found in E. coli. PhoD was originally discovered as a signal 
peptide a Tat substrate in Bacillus subtilis and the version of the PhoD signal peptide 
used in this study has a mutation within the h-region (amino acid underlined in Table 
1) (Pop et al., 2002; Gerlach, Pop and P., 2004). The last presented signal peptide is 
that of HyaA. HyaA is also found natively in E. coli and the HyaA signal peptide has 
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successfully transported proteins by Tat (Mori and Cline, 1998; Palmer, Sargent and 
Berks, 2005). 
 
1.5.3. Disulphide bond formation in the cytoplasm 
As previously discussed, proteins may require disulphide bond formation to be folded 
correctly and maintain stability. It has been suggested that many proteins exported by 
the Tat pathway have to be correctly folded before transport because they contain 
cofactors that are enzymatically inserted in the cytoplasm (Rose et al., 2002; Dilks et 
al., 2003; Palmer and Berks, 2012; Frain, Robinson and van Dijl, 2019). 
It was thought that the reducing environment in the cytoplasm was incompatible with 
disulphide bond formation (Mallick et al., 2002). However, deleting the two main 
reducing pathways (∆gor/∆trxB) allows disulphide bonds to form in the cytoplasm 
(Prinz et al., 1997). The pathways involved in cytoplasmic disulphide bond formation 
are still poorly understood (Hatahet, Boyd and Beckwith, 2014). In this study, we 
support disulphide bond formation by providing eukaryotic protein disulphide-
isomerase (PDI) and sulfhydryl oxidase (ErV1p) on the expression plasmid instead of 
using a ∆gor/∆trxB double mutation. The system has been called CyDisCo after 
‘cytoplasmic disulphide bond formation in E. coli’ and efficient export of a disulphide-
bonded protein in CyDisCo strains has been presented by the Colin Robinson lab 
(Matos et al., 2014; Alanen et al., 2015). 
It has been shown that chaperones are involved in the cytoplasmic folding process, 
such as in integrating cofactors and folding chaperones that promote assembly of 
enzymes (Turner, Papish and Sargent, 2004) and their role in the Tat pathway will be 
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further discussed at a later stage. After the disulphide bond formation, proteins are 
directed to the Tat translocase embedded in the cytoplasmic membrane. 
 
1.5.4. Tat specific translocation in E. coli 
E. coli is a Gram-negative bacterium and its Tat translocon is built up of the three 
cytoplasmic membrane proteins, TatA, TatB, TatC (Ize et al., 2003). TatB and TatC 
build a complex where each of the membrane proteins occurs six to eight times 
building sub-domains (Bolhuis et al., 2001; Tarry et al., 2009). The predicted 
molecular weight of the TatBC complex is approximately 600 kDa and the TatA 
complex has been found in variable sizes. This suggests the possibility of variable 
sizes in the full TatABC complex but that has not been confirmed yet (Palmer, Sargent 
and Berks, 2005; Leake et al., 2008; Baglieri et al., 2012). 
In the first step, the Tat signal peptide interacts with a conserved surface patch on the 
cytoplasmic face of TatC and therefore interacts with the TatBC complex (Rollauer et 
al., 2012). This step does not require energy. The proofreading mechanism of the Tat 
pathway might be involved in the targeting of the substrate to the TatBC complex 
(Kostecki et al., 2010). The proofreading mechanism will be discussed at a later point. 
The binding of the signal peptide promotes conformational changes in TatB, 
displacing TatB from the TatC binding site, allowing TatA to bind to TatC (Gérard 
and Cline, 2007; Alcock et al., 2016; Habersetzer et al., 2017). TatA forms the protein 
conducting channel (Jack et al., 2004). Researchers could show that the twin-arginine 
motif of the signal peptide is interacting with TatC (Alami et al., 2003; Gérard and 
Cline, 2006), shown in Figure 9A. The assembly of the TatABC complex is proton-
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motive force (PMF) dependent (Mould and Robinson, 1991; Cline, 2015). The 
TatABC complex is presented in Figure 9B. It is not known how the substrate passes 
through the membrane. A recent model suggests that the TatA oligomer facilitates 
translocation by weaking the cytoplasmic membrane. This is based on fluorescence 
data showing that the TatA hinge region and N-terminal part of the TatA amphipathic 
helix move toward the membrane surface which correlated with membrane 
weakening. Further data shows that TatA oligomers smaller than 25 TatA subunits are 
unstable in the lipid bilayer creating bilayer ruptures. Crosslinking shows that 
oligomers are build-up of eight to 16 TatA subunits. The existence of oligomers with 
less than 25 TatA subunits suggests that the translocase creates an environment 
permitting the assembly of bilayer-destabilizing TatA oligomers (Berks, 2015; Cline, 





Figure 9: Signal peptide interaction with the TatBC complex. A The signal peptide 
interacts with the TatBC complex. Throughout that interaction, the Arg-Arg motif binds to 
TatC whilst the substrate is near TatB. The proton-motive force causes the substrate – signal 
peptide compound to bind more tightly. B Then, TatA interacts with the TatBC complex 
building a oligomeric ring structure and the substrate crosses the membrane. 
In the next step, the substrate presumably passes through the TatABC complex and 
the signal peptide is cleaved of by signal peptidase (Figure 10A). It is not known 
whether in this step of the translocation process further energy from the PMF is 







Figure 10: Signal peptide cleavage. A When the mature protein (yellow) passes through 
the passenger domain, the signal peptide will stay bound to the TatBC complex (purple and 
blue) which maintains it in the cytoplasm. The cleavage site of the signal peptide is in the 
periplasm and the signal peptide gets cleaved off by the signal peptidase (green). It is not 
known whether the signal peptide follows the substrate or whether it is degraded in the 
cytoplasm. B After the mature protein has been cleaved off the signal peptide, TatA (red) 
changes back to its original state. 
 
Once the signal peptide is cleaved off and the mature protein is released into the 
periplasm, TatA depolymerases from the TatBC complex, as shown in Figure 10B, 






1.5.5. Proofreading and quality control of the Tat translocon 
Proofreading of proteins is essential for the organism. Most proteins exported over the 
Tat pathway are essential for the viability of the cell and many of those proteins 
contain cofactors. 18 out of 30 of the E. coli native Tat substrates require the insertion 
of redox cofactors (Palmer, Sargent and Berks, 2005). The proteins need to be 
correctly folded to maintain viability of the cells but also, the Tat translocase needs to 
prevent export of proteins that are not fully folded (Miot and Betton, 2004). A number 
of the complex Tat substrates, such as TorA, are dependent on the insertion of 
cofactors. TorD is a proofreading chaperone for TorA which is essential for the 
assembly and stability of TorA. Furthermore, TorA maturation improves by two to 
three fold when TorD is present (Genest et al., 2005; Dow et al., 2013). 
As previously discussed, Tat exports folded proteins and appears to reject misfolded 
proteins. The Tat system appears to use two stages of proofreading activity. On the 
first stage proofreading is carried out by the proteostasis network. Additionally, there 
appears to be a second stage of proofreading which occurs at the Tat translocase itself. 
The Tat translocase rejects substrates that are not correctly folded or are not recognised 
as a Tat substrate (Delisa, Tullman and Georgiou, 2003; Turner, Papish and Sargent, 
2004). 
The possibility of a Tat specific proofreading at the Tat translocon has been suggested 
in some studies (Delisa, Tullman and Georgiou, 2003; Richter and Brüser, 2005; Lim 
et al., 2009; Robinson et al., 2011). It has been shown that PhoA (a Sec substrate) that 
requires periplasmic disulphide bond formation can be exported via the Tat pathway 
if a Tat signal peptide is attached and disulphide bond formation in the cytoplasm is 
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enabled (Richter and Brüser, 2005). The protein is not exported in wild type strains, 
showing that a correct 3D structure is required for transport by Tat. Another research 
group shows that alkaline phosphatase, scFv, and FAB cannot be exported by the Tat 
pathway in the absence of disulphide bonds (Delisa, Tullman and Georgiou, 2003). 
Furthermore, used the proofreading mechanism has been used as a Tat-mediated 
genetic selection technique to identify soluble protein domains of mammalian cells 
(Lim et al., 2009). 
In the first step, the chaperones interact with the substrate and suppress transport until 
folding has occurred. This may be achieved by chaperone shielding the Arg-Arg 
sequence in the signal peptide to prevent a prematurely targeting to the Tat pathway 
(Santini et al., 1998). In the second step, the substrate is folded, and cofactors are 
integrated where necessary. Typical cofactors found in Tat substrates are iron-sulphur 
and iron-nickel clusters, copper but also molybdopterin and FAD (Berks, Palmer and 
Sargent, 2003). In the third step, the substrate is released and is escorted to the Tat 
pathway (Jack et al., 2004; Hatzixanthis et al., 2005; Robinson, Cristina F. R. O. 
Matos, et al., 2011). 
As previously discussed in the section 1.3 Protein folding in bacteria, chaperones are 
a crucial factor for the proteostasis network. Some chaperones, such as TorD, are 
specifically involved in the translocation of Tat substrates. Additionally, work from 
different research groups suggests a Tat specific proofreading located at the translocon 
itself. However, the mechanism behind that is not understood. Research shows that 
the deletion of the last 40 residues of TatA does not impact the export capability and 
are dispensable for the translocation of substrates of the Tat translocon. The same has 
been found for the last 70 residues of TatB (Lee et al., 2002). The function of the 
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truncated sequences is not known and the question arises how the truncations influence 
the recognition and rejection of Tat substrates. 
Both, the Sec and the Tat pathway, have advantages and disadvantages for expressing 
biopharmaceuticals. The Sec pathway exports a variety of proteins; however, it is not 
capable of exporting complex proteins that require cofactor binding in the cytoplasm, 
or which fold too quickly for the Sec system to handle. In comparison, the Tat pathway 
is capable of exporting complex proteins but is limited in the substrates that are 
exported. This makes the Tat pathway a fascinating tool for biotechnology. 
Another tool for biotechnology can be manipulating the protein export mechanisms. 
Therefore, we have additionally been investigating the Agrobacterium tumefaciens 
Tat mechanisms and its proofreading ability. 
 
1.6. Agrobacterium tumefaciens Tat translocation system 
Agrobacterium tumefaciens (A. tumefaciens) is a Gram-negative soil bacterium that is 
pathogenic to plants. It is known for its ability to infect the plant with its own DNA 
and integrates the DNA into the plant chromosome from where it induces non-
necrotising tumours (Alfano and Collmer, 2001; Hohn, 2001).Three different protein 
secretion systems are found in A. tumefaciens and the Tat system is one of them (Wood 
et al., 2001). It has been shown that the Tat system is essential for the infection of 
plant cells and the assembly of the flagellum (Ding and Christie, 2003). A. tumefaciens 
tat operon encodes TatABC, additionally the genome contains two tatD genes. One of 
the tatD genes is located 200 kb away from the operon. The other tatD gene is located 
on an accessory plasmid called pATC58 (Wood et al., 2001; Ding and Christie, 2003). 
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It has been predicted, that TatA, TatB, and TatC are similarly integrated into the 
cytoplasmic membrane as they are in E. coli and TatA and TatB are crossing the 
membrane once and TatC crosses the membrane six times (Ding and Christie, 2003). 
A. tumefaciens is mostly known for its infectious behaviour towards plants and the 
translocation of proteins by the Tat system has not been researched extensively. Ding 
and Christie showed that A. tumefaciens is also able to export TorA-GFP expressed 
from a plasmid into the periplasm (Ding and Christie, 2003). Due to the ability to 
export TorA-GFP and a similar cytoplasmic membrane topography, A. tumefaciens 
tatABC is an interesting target operon for replacing the E. coli tatABC operon. 
After looking into how to manipulate the host organism for protein production a 
further tool for optimising protein expression for biopharmaceutical production can be 
changing the promoter of expression plasmid. 
 
1.7. Influence of the promoter on protein expression 
Bacterial protein expression is naturally controlled by promoters (Haugen, Ross and 
Gourse, 2008). As the previous example of the cold-inducible cspA promoter shows, 
promoters are a powerful tool for recombinant protein production (Miroux and 
Walker, 1996; Mujacic and Cooper, 1999). The main requirements for a promoter in 
industry are its strength, its transcriptional activity needs to be tightly controlled, and 
the induction needs to be independent of components of common culture media 
(Makrides, 1996; Terpe, 2006). The strength of a promoter in regard to the target 
protein production is typically measured in the ability to express a high amount of total 
cellular protein. About 15 to 30% of total cellular protein is considered strong and in 
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rare occasions up to 50% of total cellular protein can be achieved (Miroux and Walker, 
1996; Terpe, 2006). 
Control of the transcriptional activity has a huge impact on protein production, 
especially when the desired protein has toxic effects for the cell and prevents further 
cell growth. Therefore, the protein yield is being affected. An example for such a 
protein is bovine pancreatic DNaseI. DNaseI cleaves double-stranded DNA when it is 
expressed in an active state and leads to cell death when active DNaseI accumulates 
inside the bacterial cell. DNaseI could not be expressed in E. coli using a tac promoter, 
presumably because the basal expression level of the tac promoter in absence of an 
inducer leads to the production of fully active DNaseI. The research group had to use 
the pDOC55 plasmid under the control of the λpL promoter making the promoter 
tightly controlled in absence of an inducer (Doherty, Connolly and Worrall, 1993). 
Therefore, using the right promoter is essential for the quality and efficiency of the 
export of the target protein and can reduce cell stress (Kawe, Horn and Plückthun, 
2009). 
An additional requirement on promoters has evolved in recent years. With the 
developing recombinant protein production market in South East Asia, focus has 
shifted to the inducer required for the promoter (Wang, Chen and Tsai, 2012). 
Common inducers have been arabinose and Isopropyl-β-D-thiogalactopyranosid 
(IPTG). IPTG is an expensive reagent to use and it can be toxic to the cells therefore 
there is a clear need for alternative promoters that are tightly regulated (Figge et al., 
1988; Thermo Fisher Scientific, 2020). Promoters that are commonly used for 
industrial purposes include, for example, the lac or tac promoters, which are both 
IPTG induced, see Table 2 (Gronenborn, 1976; Brosius, Erfle and Storella, 1985; 




Table 2: Promoters commonly used for recombinant protein expression in E. coli. The 
majority of promoters are induced by adding IPTG and the promoter strength can be varied 
by the concentration of IPTG added. 
Espression system the 




lac promoter IPTG (0.05 – 2.0 mM) (Gronenborn, 1976) 
grac promoter IPTG (0.05 – 2.0 mM) (Phan, Nguyen and 
Schumann, 2012) 
trc and tac promoter IPTG (0.05 – 2.0 mM) (Brosius, Erfle and 
Storella, 1985) 
araBAD promoter (pBAD) L-arabinose (0.001 – 
1.0%) 
(Guzman et al., 1995) 
cspA promoter Thermal induced (Mujacic and Cooper, 
1999) 
T7 IPTG (Studier, 1991) 
 
To design a novel promoter system, promoter sequences in microorganism are 
identified. Common promoter sources are E. coli, λ, and T7 (Makrides, 1996). The 
assembly of a promoter is essential for its effectiveness. Moving the operator of the 
lac promoter within the promoter has shown that the level of expression is majorly 
impacted (up to 70-fold difference in the repression) which shows how challenging 




In this work, a novel promoter is tested for its ability to control recombinant protein 
production. The promoter is based on the E. coli K-12 narG operon promoter which 
controls the expression of the Nar nitrate reductase. Nitrate and nitrite are used as 
electron acceptors for respiration, the nitrate is reduced to nitrite and then in a 
secondary step reduced to ammonium (Trivedi and Ju, 1994; Lin and Stewart, 1997). 
This is shown in the following to equations: 
 
(1) 𝑁𝑂3
− + 𝑁𝐴𝐷𝐻 + 𝐻+ → 𝑁𝑂2
− + 𝑁𝐴𝐷+ + 𝐻2𝑂 
(2) 𝑁𝑂2
− + 3𝑁𝐴𝐷𝐻 + 5𝐻+ → 𝑁𝐻4
+ + 3𝑁𝐴𝐷+ + 2𝐻2𝑂 
 
E. coli can only utilise nitrate under anaerobic conditions. The genes encoding the 
nitrate reductase are not expressed when O2 is present (Richardson and Watmough, 
1999; Merrimack Pharmaceuticals, 2016). The native promoter is additionally 
controlled by two transcription factors FNR and NarL. FNR is inactivated by oxygen 
and when oxygen levels are low or oxygen is absent, FNR binds to the narG promoter 
to activate transcription. However, the narG promoter also requires activation by NarL 
which only occurs when nitrate is present in the medium (Walker and DeMoss, 1992). 
The narG-CC promoter used in the current studies is a fusion of the narG promoter 
and the CC (-40.5) promoter, the upstream of the promoter carries NarL, and 
integration host factor (IHF) sites from pnarG and the downstream region cyclic AMP 
receptor protein (CRP) site from CC (Figure 11). This promoter has been designed by 
the Steve Busby lab at the University of Birmingham. CRP functions as an activator 
within the promoter system (Browning, Butala and Busby, 2019). NarL fulfils the role 
of a regulator and activator (Andrew J. Darwin and Stewart, 1996). CRP is a strong 
activator when it is at position -41.5 upstream of the transcriptional start site. When it 
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is at position -40.5, however, CRP is less active and the promoter requires another 
transcription factor (Rossiter et al., 2011, 2015). At this promoter, the CRP binding 
site is located at position -40.5 and, therefore, CRP is less active and requires support 
from NarL. This ensures that the promoter is responsive to nitrate. 
 
Figure 11: The figure shows a schematic presentation of the narG-CC (-40.5) promoter. 
The location of the binding sites for NarL, IHF and CRP are indicated. The start site of 
transcription is shown by a bent arrow. (Adapted from a presentation given by Douglas 
Browning at the Recombinant Protein Production 10 conference). 
 
1.8. Aims and objectives 
The primary aim of this project is to develop systems to improve recombinant protein 
export using genetic engineering and promoter change. E. coli is a strong protein 
expression host with many benefits. However, the established protein expression 
pathway (Sec pathway) has its limit. The Tat pathway could expand the landscape of 
protein expression in bacteria and purification of proteins from the periplasm has 
benefits in the downstream process (Quax, 1997). Therefore, the preferred pathway 
for protein translocation is the Tat pathway and we aim to improve the understanding 
of Tat export and exploit its limits as well as establishing a new tool for recombinant 
protein production. 
In this study, we have successfully replaced the E. coli tatABC operon with the tatABC 
operon from A. tumefaciens. We aim to test the limits of the developed strain and 
investigate whether the tat operon of A. tumefaciens allows us to avoid proofreading 
mechanisms in place. 
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Furthermore, the research objectives have been to establish whether TatABC from A. 
tumefaciens can complement the E. coli ∆tat phenotype and changes E. coli TatABC 
selectiveness. 
We also aim to test a promoter based on the nitrate pathway in E. coli and see whether 
the narG-CC promoter can improve export in general and supports Tat export. 
Additionally, we are interested in the novel enzyme PETase and aim to investigate 
whether the enzyme can be expressed in an active state into the periplasm by the Tat 





2. Materials and Methods 
 
2.1. Supplies of chemicals, reagents and equipment used 
 
All reagents, materials and equipment were obtained from the companies listed below. 
 
Acros Organics: Trimethylamine N-Oxide dihydrate 98%,Methyl violgen 98% 
Beckman Coulter Inc (USA): TL-100 Ultracentrifuge TLA 100.3 rotor; Avanti J-25, 
JA10 rotor; DU 730 UV/Vis Spectrophotometer 
Bio-Rad (USA): Agarose; Bio-Rad Chemidoc XRS+; Bio-Rad Mini-PROTEAN 
Cayman Chemical: Nitrate/ Nitrite colorimetric assay 
Eppendorf: 1.5mL centrifuge tubes; PCR tubes; Centrifuge 5417R; pipette tips  
Eurofins (UK): Oligo’s/Primers 
Fisher Scientific (UK): Anti-his (C-term) unconjugated antibody; dNTP nucleotide 
mix; GeneRuler (100 bp and 1 kb); Mircobiological spreaders; Inoculation loops; 
Nanodrop 2000c 
Formedium (UK): PBS 
GE healthcare (UK): ECLTM detection reagents; PVDF and nitrocellulose membrane 
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GenPure: UV/UF water purification system for MilliQ H2O 
Eppendorf: Pipettes, P2, P20, P200, P1000 
Grant: Heat block; SUB Aqua 12 Plus water bath 
Greiner Bio-one: Universals; Easy load tips 
IBA Lifescienes: Anti-strep HRP conjugate 
IDT: Oligo’s/Primers 
Infors (Switzerland): Multitron Pro shaking incubators; Minifors 2 fermenters 
Invitrogen (USA): Anti-hexahistidine (C-term) conjugated 
Leica: Type F immersion liquid, DFC9000 GT, DMR 
Life technologies (USA): BSA 
MSE: Soniprep 150 plus 
New England Biolabs (UK): Phusion high fidelity DNA polymerase (2U/ μL); 
Restriction enzymes; NEB® Turbo compotent cells; Monarch PCR & DNA Cleanup 
kit, NEB® BL21 DE3 competent cells; Coloured protein standard broad range(11-
245kDa) Monarch Gel Extraction Kit; Antarctic Phosphatase 
Panasonic: Heated static incubator 




Quiagen (Germany): QIAprep Spin Miniprep Kit, Ni-NTA Spin column purification 
of 6xhis tagged proteins under native conditions from E. coli cell lysate 
Roche applied science (UK): T4 DNA ligase 
Sarstedt: Serological pipettes; 15mL and 50mL falcon tubes; Petri-dishes 92x16 mm; 
Filter tips; 1 mL cuvettes 
Sigma-Aldrich (UK): Lysozyme; Anti-flag HRP conjugate, LB Broth, Nitrite/ Nitrate 
colorimetric 
Starlab: Starguard comfort gloves 
Thermo Fisher Scientific Inc (USA): Nanodrop 2000c; Megafuge 16R Centrifuge, 












2.2. DNA techniques 
2.2.1. Preparation of plasmid DNA 
For preparing the plasmid DNA, Qiagen QIAprep Spin Miniprep Kit was used per 
manufacturer’s instruction. The plasmids were eluted in 50µL elution buffer (10mM 
Tris-Cl pH 8.5). Finally, the concentrations were determined using the Nanodrop. 
 
2.2.2. Preparation of genomic DNA 
For preparing genomic DNA, the GeneJET Genomic DNA Purification Kit was used 
per manufacturer’s instruction. The DNA was eluted in 200µL elution buffer (10mM 
Tris-Cl, pH 9.0, 0.1mM EDTA). The concentrations were determined using the 
Nanodrop. 
 
2.2.3. Amplification of DNA via Polymerase Chain Reaction 
PCR’s were performed using Bio-Rad T100TM Thermal Cycler. Each contained, 
1.5µL template DNA (80–100ng) or 1.5µL of colony mix (colony diluted in 20µL 
dH2O). Furthermore 0.5µL Phusion high fidelity DNA polymerase, 1µL dNTP mix, 
10µL 5X Phusion HF buffer, and one 1µL each of forward and reverse primer (0.5µM) 
were added and the mix was made up with 50µL with autoclaved dH2O). The primers 




An example cycle is given below: 
Initial denaturation 98°C 2mins  
Denaturation 98°C 10sec 
x35 cycles Annealing 58°C 30sec 
Elongation 72°C 2mins 30sec 
Final extension 72°C 10min  
Hold 4°C ∞  
 
Table 3: Cloning primers used in this work. Primers have been supplied either by Eurofins 
or integrated DNA technologies (IDT) as stated in the table. 
Primer name Sequence 5’ → 3’ Supplier 
pMA-RQ_F GAAGGCCGTCAAGGCCGCAT Eurofins 





























































































2.2.4. Purification of DNA from the genome 
PCR products were purified for sequencing using NEB Monarch PCR & DNA 
Cleanup Kit as per manufactuer’s instructions. The PCR product was eluted in 20µL 
elution buffer (10mM Tris, 0.1mM EDTA, pH 8.5 elution buffer) and the 
concentration was measured using the Nanodrop. 
 
2.2.5. Agarose gel electrophoresis 
DNA was run on agarose gels containing 1% (w/v) agarose diluted in 1x TAE buffer. 
1x TAE buffer was made from 50x TAE stock solution (242 g/L Tris, 57.1 mL/L 
glacial acetic acid, 100 mL/L 0.5 M EDTA pH8). The 1x TAE and agarose were in a 
beaker boiled in the microwave for 1min until the agarose has dissolved. Depending 
on the size of the agarose gel electrophoresis either 50mL 1x TAE buffer and 0.5g 
agarose or 150mL 1x TAE buffer and 1.5g agarose were used. The DNA samples were 
mixed with SYBR Green Nucleic Acid Gel stain and 6x Gel loading buffer before 
loading into the wells of the solidified gel. Electrophoresis was carried out at 120V 
for 30 to 50 mins depending on the expected sizes. For the visualisation of the agarose 
gels a Bio-Rad Gel doc was used. 
 
2.2.6. Purification of DNA from agarose gels 
Under UV transilluminescence the bands are visualized to cut out the desired DNA 
fragments from the agarose gel using a scalpel blade. Using the Monarch DNA Gel 
Extraction Kit the DNA was cleaned up. DNA was eluted in 20µL elution buffer and 




2.2.7. Restriction Digests of DNA 
For restriction digests, typically 1µg of DNA was used and mixed up with 5µL 10x 
Cutsmart NEB buffer and 0.25µL of each enzyme (Table 4). The total reaction volume 
was made up to 50µL with MilliQ water. The reaction was incubated for 2hours in a 
37°C heat block. To the backbone restriction digest, 2.5µL antarctic phosphatase and 
5µL 10x Antarctic Phosphatase Reaction Buffer was added after 1hour and 30mins. 
After incubation, the backbone reaction mix was heat shocked at 80°C for 2min to 
inactivate the antarctic phosphatase. Then, the reaction mix was run as described in 
2.2.5 on an agarose gel electrophoresis and purified. 
 
Table 4: Restriction enzymes used in this work. 











2.2.8. Ligation of DNA fragments into plasmid vector backbone 
For a 10µL ligation mix 1µL T4 DNA ligase, 1µL 10x T4 ligase buffer was used. 
Furthermore, the used insert to vector ratio used was typically 3:1. The ligation was 
incubated for 1 to 3 days at 4°C and then transformed. 
 
2.2.9. Gibson assembly cloning 
For constructs designed by Gibson cloning a 20 µL reaction mix was prepared using 
a 1:10 dilution of the primers. PCR’s were performed using Bio-Rad T100TM Thermal 
Cycler. Each contained, 0.3µL template DNA (80–100ng). Furthermore 0.1µL 
Phusion high fidelity DNA polymerase, 0.4µL dNTP mix, 4µL 5X Phusion HF buffer, 
and one 0.8µL each of forward and reverse primer were added and the mix was made 
up with 13.6µL with autoclaved dH2O. As previously described the samples were 
visualized using agarose electrophoresis. After adding 0.5µL DpnI to each sample, the 
samples were incubated for 1 hour at 37˚C. 
The Gibson assembly mix was set up as described in Table 5 and the assembly mix 
was incubated for an hour at 50˚C before transformation into NEB Turbo competent 
cells. 
 
Table 5: Gibson assembly composition. 
 Concentration 
Amount of each DNA fragments 0.02 – 0.5 pmols 
Gibson Assembly Master Mix (2x) 10 µL 




2.2.10. Sequencing of plasmid DNA 
For this study, the sequencing service of GATC and GENEWIZ was used. Typically, 
80 to 100ng of DNA was mixed with 5µL of 5mM sequencing primer (Table 6). 
 
Table 6: Sequencing primers used in this work. Primers have been supplied either by 
Eurofins or integrated DNA technologies (IDT) as stated in the table. 
Primer name Sequence 5’ → 3’ Supplier 
HR1_pDocK CAGCTTCAAAAGCGCTCT Eurofins 
HR2_pDocK CAATTTCACACAGGAAACAGC Eurofins 
pDocInsertF CCTCCAGCGCGGGGATCTCATG Eurofins 
pDocInsertR GGCAGGTGGTCTGATCGCCTGG Eurofins 
Tat7R GCAATAACCAGCAGTTCGCTCC Eurofins 
Tat13R AGGTACGCAGCATATTCGGC Eurofins 
pET22b insR TTATTGCTCAGCGGTGGCAG Eurofins 
ptacF_seq GAGCGGATAACAATTTCACACAGG IDT 
t7R GCTAGTTATTGCTCAGCGG Eurofins 
CM_pET23_SEQF AGCTGTTGACAATTAATCATCGGCT Eurofins 
 
2.2.11. Sequencing of genomic DNA 
For this study, the sequencing service of GATC was used. 80 to 100ng of DNA was 
mixed with 5 µL of 5 mM sequencing primer. The genomic DNA pieces send for 
52 
 
sequence were about 2000 bp large and were cloned out of the genome using the 
primers presented in Table 7. 
 
Table 7: Primers used for sequencing the E. coli genome. 
Primer name Sequence 5’ → 3’ Supplier 
UbiB_genome F GCCTTTCCTGGAGTCGTGG Eurofins 
rfaH_genome R CGAAAGACAGGCTGTGAATTGCC Eurofins 
 
2.2.12. Constructs used in this study 
A variety of constructs has been used in this study, which are presented in Table 8. 
Genes that have been synthesises for cloning have been ordered from ThermoFisher. 
 
Table 8: Plasmid construct used in this work. 
Plasmid name Function Tag Reference 
pACBSR pACBSR  (Lee et al., 2009) 
pDoc-K pDocK   (Lee et al., 2009) 





 This study 




















pSB25 pET-21b(+)-Is-PETase-W185A His6 (Austin et al., 
2018) 








pSB28 pET20b narG scFv(cobra) his6 His6 This study 
pSB29 pET22b ptac scFv(cobra) his6 His6 This study 
pSB30 pYU49-TorA-GFP-his6 His6 This study 
pSB31 pEXTII-TorA-PETase-his6 His6 This study 
pSB33 pEXTII-HyaA-PETase-his6 His6 This study 
pSB34 pEXTII-HyaA-PETase-
his6+CyDisCo 
His6 This study 
pSB35 pEXTII-AmiC-PETase-his6 His6 This study 
pSB36 pEXTII-AmiC-PETase-
his6+CyDisCo 
His6 This study 
pSB42 pYU49-TorA-R16-
his6+CyDisCo 
His6 This study 
pSB43 pYU49-TorA-ProteinG-
his6+CyDisCo 





2.2.13. Gene doctoring 
To construct strains containing TatABC homologues the gene doctoring method 
described in Lee et al. was used (Lee et al., 2009). The ubiB region and rfaH region 
were synthesized and cloned into pDoc-K plasmid with SalI – NdeI, and KpnI – 
HindIII were used to clone the Tat inserts into the plasmid. 
The pDoC-K plasmid containing the homology regions and Tat inserts (200 μg/ml 
ampicillin and 50 μg/ml kanamycin) were transformed with pACBSCE (35 μg/ml 
chloramphenicol) into MC4100 and plated onto LBA plates containing 5 % sucrose. 
One colony was used to inoculate 1 mL LB containing appropriate antibiotics and 0.5 
% glucose at 37 ºC for 2 hours whilst shaking. The cells were spun down for 2 mins 
at 18000 x g and resuspended in 1 mL LB with 0.5 % L-arabinose and incubated at 37 
ºC for 4 hours at 250 rpm. Cultures were plated on LB plates containing 50 μg/ml 
kanamycin and 5% sucrose and incubated O/N at 30 °C. For testing for positive strains 
the colonies were patched onto plates containing ampicillin and chloramphenicol and 
positive clones were send to with primers homologous to chromosomal DNA. 
 
2.3. Maintenance of E. coli cultures 
2.3.1. Media and supplements 
Unless otherwise stated, Leuria Bertani (LB) medium was used as a culture medium. 
Table 9 describes all media used in this study. For some of the work, alternative media 
have been used, see Table 9. LBA (LB with the addition of 10 g/L bacto-agar) was 
used for growth on plates. All were supplemented with appropriate antibiotic. 
Ampicillin (100 μg/mL) and Kanamycin (50 μg/mL) were dissolved in water whereas 
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Chloramphenicol (35 μg/mL) was dissolved in ethanol. Additionally, plates with 5% 
sucrose content were used for selection. 
 
Table 9: The in this study used media and their components. 
Media Components 
LB 10 g/L sodium chloride, 10 g/L tryptone, 5 g/L yeast 
extract  
LB-GT 10 g/L sodium chloride, 10 g/L tryptone, 5 g/L yeast 
extract, 0.5 % v/v glycerol, 0.4 % w/v TMAO  
TB 24g/L yeast extract, 12g/L tryptone, 4mL/L glycerol 
Potassium phosphate buffer: K2PO4 12.5g/100mL 
and KH2PO4g/100mL  
SM6 10mL 10X SM6 trace elements, 95g/L glycerol, 
5.2g/L (NH4)SO4, 4.4g/L NaH2PO4.H2O, 4.16g/L 
citric acid, 4.03g/L KCl, 1.04g/L MgSO4.7H2O, 
0.25g/L CaCl2.H2O  
10X SM6 trace elements 104g/L citric acid, 10.06g/L FeCl3.6H2O, 5.22g/L 
CaCl2.H2O, 2.72g/L MnSO4.7H2O, 2.06g/L ZnSO4. 
4H2O, 0.81g/L CuSO4.5H2O, 0.42g/L CoSO4. 
7H2O, 0.03g/L H3BO3, 0.02g/L Na2MoO4. 2H2O  
MS medium 4.5g/L KH2PO4, 10.5g/L K2HPO4, 1g/L (NH4)2SO4, 
0.5g/L Na3C6H5O7, 0.05g/L MgSO4, 7H2O, 1mL/L 
E. coli sulphur salts, 1mL/L 1mM Sodium Selenate, 
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1mL/L 1mM Ammonium molybdate tetrahydrate, 
LB Broth 4g/L, 4mL/L glycerol, 6.4g/L C4H2Na2O4 
E. coli sulphur free salts 82g/L MgCl2, 7H2O, 10g/L MnCl2, 4H2O, 4g/L 
FeCl2, 6H2O, 1g/L CaCl2, 20mL concentrated HCl 
1mM Sodium selenate 0.19g/L Na2O4Se 
1mM Ammonium 
molybdate tetrahydrate 
1.24g/L (NH4)6Mo7O24, 4H2O 
 
2.3.2. Transformation of competent E. coli cells 
Throughout the here presented work a variety of strains has been used. These are 
shown in Table 10. 
 
Table 10: Representation of the E. coli strains used in this work and their genotypes. 
Strain Genotype Reference/ source 
MC4100 AraR, F2 arD139 
DlacU169 rspL150 relA1 
flB5301 deoC1 ptsF25 
rbsR 
 
NEB® Turbo Competent 
E. coli  
F’ proA+B+ lacIq 
∆lacZM15 







MC4100 ∆tatABCDE  MC4100 with ∆tatABCDE 
deletion 
Tracy Palmer – Newcastle 
University 
N11 K-12 with ∆narG deletion Douglas Browning – 
University of 
Birmingham 
Tn3.1 W3110 carrying a Tac 
promoter upstream of 
tatABCD and ∆narG 
deletion 
Douglas Browning – 
University of 
Birmingham 
BL21 TE BL21 carrying a pTac 
promotor upstream of 
tatABCD 
(Browning et al., 2017) 
 
The E. coli strains used in this study (Table 10) were typically inoculated in 5 mL LB 
medium and cultured at 37 °C, 220 rpm. After minimum of 18 hours, 100 µL of the 
pre-culture was inoculated into 10 mL of fresh LB medium and incubated at 37 °C, 
220 rpm until an OD600 of approximately 0.5 was reached. The cells were spun down 
at 1690 x g, 4 °C for 10 mins and the supernatant was discarded. The cell pellet was 
re-suspended in 10 mL 100 mM MgCl2 (ice-cold) and were incubated for 5 mins on 
ice. Cells were spun down as previously and re-suspended in 1 mL ice-cold 100 mM 
CaCl2 and were incubated on ice for 1 hr. 
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The transformation was performed on ice, where 50 to 100 µL E. coli cells were 
incubated with 100 ng DNA for 30 mins. In a 42 °C water bath, the cells were heat 
shocked for 25 to 30 secs and immediately placed back on ice for 2 mins. The cells 
were recovered in LB, in 3:1 LB to cells, for 1 hr at 37 °C and plated on LBA with 
appropriate antibiotics. Plates were inverted and incubated O/N in the plate incubator 
at 37 °C or left at RT for 2 days. 
 
2.3.3. Storage of E. coli cells 
Cells were stored at -80 °C as a glycerol stock. Glycerol stocks were prepared using 
750 µL 50% glycerol and 750 µL stationary phase culture. 
 
2.4. Protein production and E. coli cell fractionation 
2.4.1. Cell culture and induction of plasmids 
For cell culture assays with induced plasmids, a 5 mL pre-culture was set up with E. 
coli cells containing the required plasmid and were grown O/N at 37 ºC, 220 rpm. The 
following morning, the cultures were diluted to OD600 0.1 with fresh medium and 
appropriate antibiotic in 50 mL media in 250 mL Erlenmeyer flasks. Depending on 
the used strains and plasmids different media were used and the cells were grown at 
either 30 ºC or 37 ºC. The cultures were grown until OD600 0.4 – 0.6 (mid-log phase) 
was reached. When the stationary phase was reached plasmids were induced for 




2.4.2. E. coli fermentation 
Typically, a pre-culture with 5 mL MS media and appropriate antibiotic was set up 
and grown for 6 hours at 37 ºC, 250 rpm. 2 mL of pre-inoculate were transferred to 
200 mL of SM6 media and grown O/N at 37 ºC, 220 rpm. For the inoculation of the 
fermenter, a volume of 300 
𝑂𝐷
𝐿
 was used. 
At the University of Kent, a 1.5L fed-batch fermenter from Infors, called Minifors2, 
are used. The fermenter have a fermentation volume of 0.5L is used and their 
components are presented schematically in Figure 12. The fed-batch fermenter is 
inoculated through the sample port on top of the fermenter. Furthermore, the pO2, 
temperature, and pH are monitored by sensors. Acid and base are added in relation the 
measured pH. The temperature is controlled over a cooling/ heating sleeve. The pO2 
measurements influence throughout the fermentation process the stirrer speed. 
Throughout the fermentation process, glycerol is added as a carbon source and 
samples are taken through the sample port. Furthermore, additives like the appropriate 
antibiotic or anti-foaming agent is added through a septum collar on top of the 




Figure 12: Schematic presentations of the here used fed-batch fermenter. The fermenter 
has a 1.5 L vessel and the fermentation volume is 0.5L. The fermenter is innoculted through 
the sample port with 300 
𝑂𝐷
𝐿
. The culture is continuously monitored for its pO2 and pH. 
Throughout the fermentation process acid and base are fed in relation to the measured pH. 
The stirrer is related to the pO2 measured. Furthermore, a carbon source is being supplied. 
Throughout the here presented experiments, glycerol has been used as carbon source. 
Additionally, the temperature is measured continuously, and the fed-batch fermenters 
temperature is being controlled by a cooling/ heating sleeve. The fed-batch fermenter is 
inoculated through the sample port and samples are taken through the same port. Not shown 
in the picture is the septum collar on the top of the fermenter through which the appropriate 
antibiotic and anti-foam agent is added. 
 
To prepare the fermenters for a run, they were autoclaved with 500 mL SM6 media 
and pH and pO2 probe inserted.  The temperature was set up to 37 ºC and temperature 
was maintained via a chilling mantel. Throughout the run, the pH was maintained at 
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pH 7 with 25 % sulphuric acid and 25 % ammonia. Before inoculation the pO2 probe 
was calibrated at 100% saturation. 
After inoculation the pO2 was set to cascade and the stirrers and airflow were set to 
maximum (stirring of 900 to 1600 rpm; total flow of 1.5 to 2 
𝐿
𝑚𝑖𝑛
). When stirrer and 
airflow reached their maximum, the temperature of the culture was dropped to 25 ºC. 
Throughout the run, the OD’s were monitored, and following supplements were added 
to the fermentation: 
OD 38 to 42: add 8 
𝑚𝐿
𝐿
 1 M MgSO4, 7 H2O 
OD 54 to 58: add 5 
𝑚𝐿
𝐿
 1 M NaHPO, H2O 
OD 66 to 70: add 7 
𝑚𝐿
𝐿
 1 NaHPO, H2O and begin glycerol feed (80% w/w glycerol at 
a rate of 0.3 of pump capacity) 
OD > 75: Induction with appropriate inducer. 
Induction usually was done in the late evening and samples were taken from the next 
morning onwards (approximately 15 hours post-induction). Cell samples were either 
fractioned according to the E. coli cell fractionation protocol or prepared as whole cell 
extracts. 
 
2.4.3. E. coli cell fractionation 
Cells were fractionated into their periplasmic (P), cytoplasmic (C) and insoluble (I) 
fraction using the osmotic/ cold shock method as described by Randall and Hardy, 
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1986 (Randall and Hardy, 1986). Cells were harvested and equalised to the same OD 
using the equation 10/ OD600 and were centrifuged at 1690 x g, 4 ºC for 10 mins. 
Samples were placed on ice and the supernatant was discarded. Then, cells were 
resuspended in 0.5 mL ice cold Buffer 1 (100 mM Tris-acetate pH 8.2, 500 mM 
sucrose, 5mM EDTA). 0.5 mL ice cold mqH2O and 40 µL lysozyme (1 mg/ mL stock) 
were added. The eppendorf was inverted 3 times and cells were incubated on ice. After 
5 mins 20 µL 1M MgCl2 was added to stabilise the cytoplasmic membrane, and cells 
were centrifuged at 20800 x g, 4 ºC for 2 mins. The supernatant was collected in a 1.5 
mL Eppendorf without disturbing the cell pellet. The remaining supernatant around 
the pellet was discarded and the pellet was washed with 750 µL ice cold Buffer 2 (50 
mM Tris-acetate pH8.2, 250 mM sucrose, 10 mM MgSO4) and centrifuged at 20800 
x g, 4 ºC for 5 mins. The supernatant was discarded, and the pellet was resuspended 
in 750 µL Buffer 3 (50 mM Tris-acetate pH 8.2, 2.5 mM EDTA). To fully lyse the 
cells, they were sonicated (10 secs on/ 10 secs off x 4) and then ultra-centrifuged at 
264,360 x g, 4 ºC for 30 mins. This guarantees the separation of the membrane and 
insoluble material. The supernatant was collected as cytoplasmic fraction in a 1.5 mL 
Eppendorf without disturbing the cell pellet. The remaining supernatant was 
discarded, and the pellet was resuspended in 750 µL Buffer 3 (50 mM Tris-acetate pH 
8.2, 2.5 mM EDTA). All fractions were stored at -20 ºC for further sample preparation. 
 
2.4.4. Whole cell extract 
For sample preparation without separating the cytoplasm, insoluble fraction, and 
periplasm, the cells were harvested and equalised to the same OD using the equation 
10/ OD600 were centrifuged at 1690 x g, 4 ºC for 10 mins. The supernatant was poured 
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off and the pellet was diluted in 1 mL Buffer 1. To lyse the cells, they were sonicated 
on ice for 1 min. 
 
2.5. Protein electrophoresis 
2.5.1. SDS poly-acrylamide gel electrophoresis (SDS-PAGE) 
For protein separation SDS-PAGE was used in the Bio-Rad Mini-PROTEAN® Tetra 
System. The gels are containing a separation and a stacking gel composed out of 15% 
acrylamide, 0.3% bis-acrylamide (37:5:1), 375 mM Tris-HCl pH 8.85, 0.1% SDS, 
0.1% APS and 0.06% TEMED for the separation gel. For the stacking gel 5% 
acrylamide, 0.0375 % bis-acrylamide, 125 mM Tris-HCL pH 6.8, 0.001% SDS, 0.6% 
APS and 0.06% TEMED was used. The gels were cast in the Bio-Rad 0.75 gel plates. 
For running the samples on SDS-PAGE they were mixed with protein gel loading 
buffer (125 mM Tris-HCl pH 6.8, 20% glycerol, 4% SDS, 0.02% bromophenol blue 
and 5% β- mercaptoethanol) and heated for 5 mins at 95 ºC. Gels were run at 60 mA 
for 40 mins in protein gel running buffer (25 mM Tris, 192 mM Glycine and 0.1% 
SDS at pH 8.3). 
 
2.5.2. Native gel/ CN-PAGE gel 
For native protein separation PAGE was used in the Bio-Rad Mini-PROTEAN® Tetra 
System as described in 2.5.1. The gels are containing a separation and a stacking gel 
composed out of 15 % acrylamide, 0.3 % bis-acrylamide (37:5:1), 375 mM Tris-HCl 
pH 8.85, 0.1 % APS and 0.06 % TEMED for the separation gel. For the stacking gel 
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5 % acrylamide, 0.0375 % bis-acrylamide, 125 mM Tris-HCL pH 6.8, 0.6 % APS and 
0.06 % TEMED was used. Gels were run at 60 mA for 40 mins in protein gel running 
buffer (25 mM Tris and 192 mM Glycine at pH 8.3). 
 
2.5.3. Coomassie staining 
For visualisation of the protein on SDS-PAGE the gels were incubated in 40 mL 
Coomassie stain (10 % acetic acid, 40 % methanol and 1 g/L Coomassie Brilliant Blue 
R-250 blue) for 1 hr at RT on a shaker. The stain was removed by washing the gel in 
D-stain (5 % ethanol, 7.5 % acetic acid) and replacing the D-stain 3 times over the 
period of 4 hours. 
 
2.6. Protein detection 
2.6.1. Western blotting 
Proteins were also visualised using electrophoresis for wet-western blotting. Proteins 
were transferred onto a PVDF or nitrocellulose membrane depending on the tag to be 
visualised. Proteins were transferred using the Bio-Rad system and the SDS-PAGE 
was placed on top of the membrane in between two sheets of Whatman paper and two 
sponges whilst being soaked in western blot transfer buffer (192 mM Glycine, 25 mM 
Tris and 10 % ethanol). The sandwich was placed in a cassette between the electrodes 
and the tank was filled with western blot transfer buffer. Proteins were transferred at 





For proteins immunoblotted on PVDF membrane, the membrane was stored 
overnight in 1 x PBS-T containing 2.5 % skimmed milk powder at 4ºC. On the 
next morning the membrane was washed 3 times for 5 mins in PBS-T at RT and 
then incubated for 1 hr in primary antibody. Followed by 3 more washing steps 
for 5 mins in PBS-T and incubation for 1 hr in the secondary antibody. The here 
used antibodies are listed in Table 11. The remaining secondary antibody is 
washed off in 6 washes for 5 mins in PBS-T. The membrane was treated using 
the ECLTM kit according to the manufacture’s guide and the bands were 











Table 11: Antibodies used in this work. 
Antibody Concentration Source 
Anti-TatA 1:2000 Laboratoy stock  
Anti-strep 1:32000 IBA life sciences 
Anti-GFP 1:1000 ThermoFisher 
Anti-mouse HRP conjugate 1:5000 Promega 
Anti-rabbit HRP conjugate 1:5000 Promega 
Anti-strep HRP conjugate 1:32000 IBA life sciences 
Anti-hGH 1:10000 Laboratoy stock 
(Alanen et al., 2015) 
Anti-hexastidine (C-term) 1:8000 Invitrogen 
 
For proteins transferred onto nitrocellulose membrane, the membranes were 
incubated overnight at 4ºC in 20 mL PBS-T containing 3 % BSA. At the next 
morning, the membrane was washed with PBS-T 3 times for 5 mins on the 
rocker. Then, the membrane was incubated for 10 mins in 20 mL PBS-T with 
20 µL Biotin blocking buffer. Afterwards the membrane was incubated in 20 
mL PBS-T, 20 µL anti-strep antibody and 3 % BSA for 1 hr shaking. This is 
followed by 2 1 min wash steps in PBS-T and 2 1 min was steps in PBS. The 
membrane was treated using the ECLTM kit according to the manufacture’s 
guide and the bands were visualised using BioRad Gel-doc chemiluminescence 
imager. All western blots were visualised for 60 seconds taking 100 images. 
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The here presented western blot images have been exposed between 5 and 10 
seconds. 
 
2.6.3. TMAO assay 
For testing whether the Tat systems are functional a Trimethylamine N-Oxide assay 
was done. Cell cultures were grown and fractioned as described previously and LB-
GT media was used. The samples were run on native gel as described in 2.5.2. For 
visualising the TMAO in the sample fractions the native gel was incubated for 15 mins 
in 100 mM potassium phosphate buffer containing 0.25 % w/v methyl violgen mixed 
with 10 mM sodium hydroxide buffer with 1 % sodium dithonite. After 15 mins the 
gel should be stained blue. To visualise the TMAO the gel is transferred into 100 mM 
potassium phosphate buffer containing 0.4 % w/v TMAO. 
 
2.7. Protein purification 
2.7.1. Ni-NTA Spin column purification of 6xhis tagged proteins under native 
conditions from E. coli cell lysate 
For the bench top purification the spin columns have been equilibrated with 600 µL 
NPI-10 buffer. Then the columns were centrifuged at 890 x g for 2 minutes at 4˚C. 
Then 100 µL sample has been loaded onto the column and the columns was 
centrifuged for 5 min at 270 x g at 4˚C. and the flow through was collected. Then the 
column was twice washed using 600 µL NPI-20 buffer and the column was 
centrifuged at 890 x g for 2 min at 4˚C. Both wash fractions were collected. This was 
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followed by two elution steps using 300 µL NPI-500 buffer. The column was 
centrifuged at 890 x g for 2min at 4˚C and the elution fractions were collected. The 
buffers required for the bench top purification are presented in Table 12. 
Table 12: Buffers required for the Ni-NTA spin column purification 
Buffer Components 
NPI-10 6.9 g/L NaH2PO4, 17.5 g/L NaCl, 0.68 g/L C3H4N2 
NPI-20 6.9 g/L NaH2PO4, 175.4 g/L NaCl, 1.36 g/L C3H4N2 
NPI-500 6.9 g/L NaH2PO4, 175.4 g/L NaCl, 34 g/L C3H4N2 
 
2.8. Nitrite/ Nitrate assay, colorimetric  
2.8.1. Nitrite/ Nitrate assay kit (Sigma Aldrich) 
After samples were taken from the fermenter and spun down, 2.5 µL of the fermenter 
sample were topped up with the buffer solution to a final volume of 100 µL for the 
nitrite assay and a final volume of 80 µL for the nitrate assay. Standard curve was 
prepared according to the manufacturer’s instruction. Each sample has been prepared 
in a triplicate. 
For the nitrate assay 10 µL nitrate reductase solution and 10 µL enzyme cofactor 
solution were added to each well and the samples were mixed thoroughly and 
incubated at 25˚C, shaking. After 2 hours incubation 50 µL Griess reagent A were 
added to all samples including the nitrite ones followed by 5 minutes incubation. Then 
50 µL Griess reagent B were added to each well and after 10 minutes incubation the 
absorbance (540nm) was measured. 
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Once the absorbance has been measured, the standard curve has been plotted and the 
relation of absorbance to nitrite/ nitrite and nitrate has been calculated. Then the 
concentration of nitrite (1) and nitrite and nitrate (2) has been calculated. From there 








= 𝐶[𝑁𝑂3− +𝑁𝑂2] 
(3) 𝐶𝑁𝑂3− = 𝐶[𝑁𝑂3− +𝑁𝑂2] − 𝐶𝑁𝑂2 
 
2.9. Microscopy 
2.9.1. Leica DMR microscope 
For imaging of the E. coli cells a Leica DMR microscope with attached DFC9000 GT 




3. E. coli genome modification with tatABC Agrobacterium 




The Tat pathway exists in archaea, bacteria and plant chloroplasts and the different 
organisms utilise Tat to various ends. (Berks, 1996; Dilks et al., 2003) It is known that 
the Tat pathway is capable of transporting fully folded proteins through the membrane 
into the periplasm (Matos et al., 2014; Alanen et al., 2015). Because of its unique 
ability of exporting correctly folded proteins and the ability to transport proteins up to 
a size of 150 kDa, Tat is interesting in regard to biopharmaceutical protein production 
(Jones et al., 2016). The reason why certain proteins are only transported in a folded 
state using the Tat apparatus is poorly understood. However, Richter et al. show that 
introducing six hydrophobic residues to different Tat substrates (HiPIP and FG5) 
prevents translocation. This suggests that Tat pathway tends to reject proteins with 
hydrophobic residues exposed at their surface and that translocation is restricted to 
substrates that are adequately hydrophilic on the surface. A change of surface charge 
leads to the rejection of Tat substrates (Richter et al., 2007). The proteins translocated 
by the Tat pathway are crucial for cell division, cell motility and processes like 
organophosphate metabolism which shows how important this pathway for bacteria is 
(Stanley, Findlay and Berks, 2001; Palmer and Berks, 2012). 
Possible reasons for the transport of Tat substrates in a folded state could be that the 
tools (e.g. chaperones and redox factors) required for folding are not available in the 
periplasm and therefore the protein must be transported in a folded state (Natale, 
Brüser and Driessen, 2008). This hypothesis is supported by the fact that Tat transports 
almost exclusively cofactor containing redox proteins in most organisms (Ding and 
Christie, 2003; Dilks and Giménez, 2005). Some extremophile bacteria tend to 
transport more proteins over the Tat pathway which might be related to challenges in 
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folding the proteins in the periplasm due to, for example, high extracellular salt 
concentrations (Palmer and Berks, 2012; Green and Mecsas, 2015). This might 
explain why more proteins are transported over the Tat pathway in, for example, 
Haloferax volcanii compared to E. coli (Rose et al., 2002). However, overcoming its 
proofreading mechanism is challenging (Mendel and Robinson, 2007; Jones et al., 
2016). 
In this study we aim to modify the E. coli genome to investigate if an alternative tat 
operon is capable of expressing a larger variety of proteins and to overcome the 
proofreading mechanism of E. coli Tat and test the export ability. We chose to work 
with the tat operon of Agrobacterium tumefaciens. It has been shown that the A. 
tumefaciens TatA, TatB, and TatC proteins are similarly configured compared to the 
E. coli proteins (Oates et al., 2003). TatA and TatB each transverse the membrane 
once, while TatC transverses the membrane six times. However, A. tumefaciens tat 
genes are not closely related to E. coli tat genes (see Table 13) and an alignment is 









Table 13: Comparison between the A. tumefaciens Tat proteins and the E. coli Tat 
proteins. Whilst the proteins show a high similarity in the way they are embedded in the 
membrane the actual amino acid sequence varies considerably. Ding and Christie showed in 
2003 that TatA shows the highest similarity with only 42%. TatB shows 27% identity and 
TatC 35%. 
 TatA TatB TatC 
Amino acid length A. 
tumefaciens 
68 239 267 
Amino acid length E. coli 89 171 258 
Amino acid identity in % 44 31 35 
 
The questions addressed here are whether an alternative tat operon integrated into the 
E. coli genome can complement the ∆tat specific chaining phenotype. Furthermore, 
we were testing the modified strain for its ability to export Tat native substrates and 






3.2.1. Expression of Tat proteins on a secondary plasmid in ∆tat is able to 
rescue the filamentous phenotype but does not improve the growth 
In the first experiment, we evaluated which tat operons could be possible targets for 
an insertion onto the E. coli chromosome. We transformed a plasmid containing tat 
operon sequences into a ∆tat strain on plasmid pWM and compared the growth and 
phenotype. pWM is a derivative of pLysSBAD with a ∆Lys deletion. In this plasmid the 
tat operon is induced with L-arabinose. An empty plasmid would have been useful but 
a version of the pWM lacking the tat operon was not available for this work. However, 
∆tat has been transformed with a variety of plasmids in previous studies, none of 
which complemented the phenotype (Frain et al., 2017). Various operons were 
investigated, such as the tat operons of Agrobacterium tumefaciens, Mesorhizobium 
loti, and Synechocystis sp.. These were selected because they contain a tat operon on 
the genome and show varying degrees of similarity to the E. coli system. However, in 
the work presented here we focus on A. tumefaciens TatABC. 
Cells lacking a Tat system are not able to export proteins that are vital for the ability 
to separate during cell division. Therefore, these cells show a ‘chaining’ phenotype, 
Figure 13B. Under the microscope we could observe that cells expressing TatABC of 
A. tumefaciens (Figure 13C and Figure 13D) are capable of rescuing the phenotype of 
the ∆tat strain and the cells are showing a similar phenotype to MC4100 wildtype 
(Figure 13A). Cells not expressing the TatABC A. tumefaciens tat operon show the 
same phenotype as ∆tat cells not containing a plasmid, Figure 13C. The phenotype 
changes are only confirmed after the synthesis of A. tumefaciens TatABC once 
induction of expression has occurred. 
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As the A. tumefaciens tat operon is able to improve the phenotype, we expect the cells 






Figure 13: A. tumefaciens TatABC complements the ∆tat phenotype of E. coli. The 
figure shows microscope (Leica DMR microscope) images of the different phenotypes of 
A MC4100, B ∆tat which lacks proteins important for the separation of the cell membrane 
and shows a ‘chaining’ phenotype, C of ∆tat cells expressing A. tumefaciens TatABC from 
a plasmid pre-induction, and D of ∆tat cells expressing A. tumefaciens TatABC following 
induction. Cells were grown in 10mL LB in shake flask and visualized on a Leica DMR 
microscope. The tat operon was expressed of the plasmid (pWM) and expression was 




Furthermore, we transformed a plasmid containing the A. tumefaciens tat operon 
sequence into a ∆tat strain and compared the growth and phenotype.  
 
Figure 14: Comparison of the growth of ∆tat expressing a plasmid containing the 
Agrobacterium tumefaciens tat operon to MC4100 wildtype and ∆tat. The growth of 
MC4100 wildtype, ∆tat cells, and ∆tat cells containing the A. tumefaciens TatABC plasmid 
pWM (with and without induction) were monitored in a plate reader in 1mL LB cultures. 
Time points were taken every 10 minutes for 12 hours. The values presented here are 
averaged values from quadruplicates. One sample of ∆tat cells containing the A. 
tumefaciens TatABC pWM (pLysSBAD ∆Lys) plasmid was induced with 20µM L-
arabinose after 2 hours. 
 
Agrobacterium tumefaciens tatABC is not able to improve growth when expressed 
from a plasmid instead it decreases the growth rate as shown in Figure 14. An empty 
vector control could have been used as a control in this experiment. However, only 
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when the plasmid containing A. tumefaciens tatABC was induced were the cells 
complemented. Cells without a functioning Tat system are prone to lysis and show a 
reduced growth rate. Here the observed decrease in growth rate may be related to the 
combination of stress that the cells experience due to the tat deletion affecting their 
viability and the expression of a foreign Tat system. Also shown in Figure 14, the 
plasmid inhibits growth and the cells containing A. tumefaciens tatABC had a lower 
yield than the ∆tat strain. The decreased cell growth yield could be related to 
overexpression of the foreign Tat systems and challenges integrating this system into 
the cytoplasmic membrane. Here we used the pWM plasmid which is a pLysSBAD 
derivative with a ∆Lys deletion induced with 20µM L-Arabinose. 
 
3.2.2. A. tumefaciens TatABC is successfully inserted on the chromosome and 
can improve the growth 
The ∆tat strain shows changes in the phenotype when a tat operon is expressed from 
a plasmid, but the growth does not improve. It had been planned to test the export 
ability of foreign Tat systems in E. coli. However, further expression experiments will 
be challenging as two-plasmid expression increases cell stress on already sick cells 
and in the previous experiment the cells expressing the tat operon showed a decreased 
growth rate. Therefore, we have chosen gene doctoring as a method to replace the E. 
coli TatABC genes on the chromosome of the strain MC4100. 
Gene doctoring consists of using the λ red genes and a transfer plasmid called pDoc-
K. The pDoc-K plasmid contains the sacB gene which is a counterselection gene that 
makes the cells sensitive to sucrose, an ampR as selection markers, a kanR as selection 
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marker, and two Sce1 restriction sites flanking the target DNA which are cut in the 
gene doctoring process (Figure 15). 
 
Figure 15: Plasmid map showing of the features of the gene doctoring plasmid pDoc-K 
including the tatABC operon of A. tumefaciens. 
To apply the pDoc-K vector for replacing the genes encoding E. coli TatABC with the 
genes encoding Agrobacterium tumefaciens TatABC, two homology regions (HR) 
have to be designed via gene synthesis. Homology regions have to align to the flanking 
gene sequence where the deletion or insertion is planned. The HR regions are about 
400 bp long and align to the UbiB and TatD region next to the E. coli TatABC genes. 
The A. tumefaciens tatABC operon had been codon optimised and the sequence is 
shown in the appendix on page 216. To express the A. tumefaciens tatABC operon the 




Figure 16: Location of the homology regions (HR1 and HR2 on the genome). For the 
gene doctoring process homology regions have to be designed which align with the target 
site on the chromosome. The homology regions are 400 bp long and in this case align to the 
ubiB and tatD genes. Throughout the process the sequence between the homology regions 
is going to be replaced. 
 
After the pDoc-K plasmid containing the HR regions, shown in Figure 16 and the 






Figure 17: Flow diagram of the gene doctoring process. In the first step, two 
recombineering plasmids are transformed into the cells. The 1st plasmid contains the λ red 
genes for the recombineering process and the 2nd plasmid is the donor plasmid of the operon 
of interest. Once the plasmid is induced with arabinose, the λ red genes are expressed. After 
a 3-hour incubation the cells are plated out on agarose plates. To confirm that the operon of 
interest has been introduced into the genome, the colonies are screened for the loss of the 
two plasmids (ampicillin resistance and chloramphenicol resistance) and the insertion of 
operon of interest by kanamycin resistance and PCR. 
 
The cells were plated out and were re-streaked to confirm a loss of the gene doctoring 
plasmid and a positive insertion on the chromosome. Cells growing on agar plates with 
kanamycin but not on ampicillin and chloramphenicol plates are a first confirmation 
of a successful gene doctoring process. The kanamycin resistance is introduced to the 
genome together with the tat operon. The recombineering plasmid confers resistance 
to chloramphenicol and the donor plasmid confers resistance ampicillin. Furthermore, 
positive clones were confirmed by creating a PCR product containing the genomic 
region of interest and showing on an agarose gel that there was an insertion (Figure 
18). Clones with the right size of insert were sent for sequencing by GATC. Two 
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colonies were confirmed to contain the A. tumefaciens tat operon on the genome E. 
coli MC4100 genome. 
 
Figure 18: DNA insert confirmation of the MC4100 colonies. A colony PCR was 
performed on the colonies that possibly contain the new operon on the chromosome. The 
expected size of the ∆tat sequence as a negative control is 1191bp and the expected size of 
the tat operons inserted into the E. coli genome are expected at a size of 3653bp for the A. 
tumefaciens TatABC. Furthermore, shown here is the work on Mesorhizobium loti which 
was not continued. 
 
Furthermore, the PCR products have been sequenced with GATC sequencing and the 
insertion of A. tumefaciens tatABC was be confirmed. The engineered E. coli MC4100 
mutants contain next to the A. tumefaciens sequence a kanamycin cassette on the 
genome. The same process was undertaken using the tatABC sequence of 
Mesorhizobium loti however, a positive insertion of the operon could not be confirmed 





With this method, we were able to confirm two colonies of MC4100 containing A. 
tumefaciens tatABC operon on the genome (Clone 1 and Clone 2). Further work has 
been continued with both colonies. The clones have been sequenced starting in the 
homology region 1 until the homology region 2 and their sequences are shown in the 
appendix (page 217 and page 218). The in the appendix shown sequence corresponds 
to the TatABC region. The nucleotide sequence of Clone 1 shows one point mutation 
which is affecting the amino acid sequence, changing a lysine to an arginine in the 
TatB sequence in position 41. The sequence of Clone 2 shows no mutations. 
The difference in the Clone 1 nucleotide sequence could have either occurred during 
the gene doctoring process or it could a be point mutation that occurred during the 
PCR use to generate the amplicon. In the next step, we investigated the functionality 
of the introduced tat in Clone 1 and Clone 2. 
A strain with a non-functional Tat pathway lacks proteins important for the separation 
of the cell membrane and shows a ‘chaining’ or filamentous phenotype. This was used 







Figure 19: Comparison of the different phenotypes of the new clones, wildtype cells, 
and ∆tat. The figure shows microscope (Leica DMR microscope) images of the different 
phenotypes of A MC4100, B ∆tat which lacks proteins important for the separation of the 
cell membrane and shows a ‘chaining’ phenotype, C of MC4100 Clone 1, and D MC4100 
Clone 2. Cells were grown in 10mL LB in shake flask and visualized on a Leica DMR 
microscope. 
 
Both clones show a phenotype that is different to that of the ∆tat strain, Figure 19. 
Clone 1 cells seem to accumulate as clumps which suggest a defect in the Tat operon. 
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However, it shows no similarity to the filamentous chaining phenotype of the ∆tat 
strain. The morphology of Clone 2 is similar in appearance to that of MC4100. 
 
Figure 20: Comparison of the growth of the two Tat clones to MC4100 and ∆tat. The 
growth of the MC4100 wildtype, ∆tat strain, and Clones 1 and 2 of the MC4100 A. 
tumefaciens TatABC strain was monitored in a plate reader in 1mL LB cultures. OD 
readings were taken every 10 minutes for 12 hours. The values presented here are averaged 
values from quadruplicates. 
 
The insertion of A. tumefaciens TatABC onto chromosome of E. coli can improve the 






3.2.3. MC4100 expressing the Agrobacterium tumefaciens tatABC operon is 
able to export the native Tat substrate TorA into the periplasm 
In E. coli TatA, TatB, and TatC proteins have to be functional to translocate their cargo 
proteins into the periplasm (Wexler et al., 2000). If trimethylamine N-oxide (TMAO) 
is provided in the medium TMAO reductase (TorA) activity will be found in the 
cytoplasmic, insoluble, and periplasmic fractions (Oates et al., 2003). However, cells 
with insufficient Tat components are not able to export TorA into the periplasm and 
TorA will only occur in the cytoplasmic and insoluble fractions. We chose the TMAO 
reductase (TorA) assay, to confirm that A. tumefaciens TatABC is able to export an E. 
coli native Tat substrate. Thus, being able to fulfil E. coli Tat roles. 
After the culture was grown for several hours in a medium containing TMAO (LB-
GT medium) the cells were separated into cytoplasmic (C), insoluble (I), and 
periplasmic (P) fractions as described in 2.4.3 E. coli cell fractionation and were 
loaded onto a native CN-PAGE gel. The gel can be stained for TorA activity and the 
TorA appears as a white band. As Figure 21 shows, the two clones containing A. 
tumefaciens TatABC on the chromosome are capable of exporting TorA into the 
periplasm when TMAO is provided in the medium. ∆tat was chosen as a negative 
control because it lacks the necessary Tat system to export TorA. TorA is visible in 
the cytoplasmic and insoluble fraction in ∆tat but not in the periplasmic fraction, as 
expected. As shown in Figure 21A, the periplasmic export of Clone 1 is similar to that 






Figure 21: Clones expressing the A. tumefaciens tatABC operon are capable of 
exporting a native Tat substrate. Cells were grown in LB medium containing TMAO 
(LB-GT medium) at 37˚C in 50mL shake flask cultures. Cells were separated in cytoplasmic 
(C), insoluble (I), and periplasmic (P) fraction. The TorA (80 kDA, arrowed) is a white 
band that will appear in the periplasm in a functional Tat system. Compared to ∆tat there is 
a clear band of TMAO in the periplasm showing that TatABC is able to export a native 
protein. A shows the CN-PAGE of the first clone (Clone1) and B shows the CN-PAGE of 
the second clone (Clone 2). The gel is a representative of two gels and 10 µL sample have 
been loaded in each well.  
 
Additionally, we aimed to confirm A. tumefaciens TatA integration into the 
membrane. Keeping in mind, that E. coli TatA shares 42% similarity with A. 
tumefaciens TatA, we have tried to detect TatA in the membrane of the new clones 
with a E. coli TatA specific antibody previously used in the lab. E. coli TatA has a 
size of roughly 10 kDa but in previous studies E. coli TatA was appearing at around 
18 kDa size in SDS-PAGE gels (Gouffi et al., 2004). The cells were grown in shake 
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flasks cultures in terrific broth (TB) medium and, as previously, separated into the 
three fractions (cytoplasm (C), insoluble (I), and periplasm (P)). 
 
Figure 22: TatA signal in MC4100, ∆tat, and the new A. tumefaciens TatABC. The cells 
were grown in shake flask at 30°C in Terrific Broth (TB) medium and then were 
fractionated into cytoplasmic, insoluble, and periplasmic fractions. TatA (arrowed) signal 
is expected in the insoluble fraction. A shows the Coomassie stained SDS-PAGE gel, B 
shows the western blot containing Clone 1, and C shows the western blot containing Clone 
2. The expected size is 9.8 kDa for E. coli TatA and 7.5 kDa for A. tumefaciens TatA. 
Samples were blotted using an anti-TatA antibody. The gel is a representative of two gels 
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and 10 µL sample have been loaded in each well. The exposure time of the western blots is 
19 seconds. 
 
In Figure 22B it was not possible to detect a TatA signal in the insoluble fraction of 
Clone 1 although as expected, it was possible to detect E. coli TatA in the insoluble 
fraction of the wildtype cells. Figure 22C shows that TatA from Clone 2 is detectable 
with an E. coli specific TatA antibody. This shows that there is a difference in the 
activity of the integrated Tat system in clones 1 and 2. The insertions have been 
sequenced and one point mutation in the A. tumefaciens TatABC region occurred in 
Clone 1 (alignment shown in the appendix page 219 and page 220). However, as the 
upstream promoter region has not been sequenced, it is possible that TatA is expressed 
at different levels in the two clones. 
 
3.2.4. MC4100 clones expressing the A. tumefaciens TatABC is not capable of 
exporting human growth hormone into the periplasm 
We are aiming to investigate the export ability and limitations of the new strain 
designed in this study. Are there any proteins that the A. tumefaciens TatABC clones 
are able to export that E. coli rejects? To answer the question, we started investigating 
if proteins that are exported by E. coli are also exported in the new strain. One protein 
that previously was exported successfully by the E. coli Tat system is human growth 




Figure 23: The detection of hGH in cytoplasmic, insoluble, and periplasmic fractions 
following expression with the Tat specific signal peptide TorA in strains encoding the 
E. coli and A. tumefaciens tat operon. The plasmid containing hGH (21 kDa, arrowed) 
was induced with 1 mM IPTG and was expressed in shake flask at 30°C in TMAO 
containing Luria Broth (LB) medium. The expression was 3 hours post-induction. A shows 
the Coomassie stained SDS-PAGE gel B shows the western blot of the fractions. The 
western blot was immunoblotted using an hGH-specific antibody. The gel is a 
representative of two gels and 10 µL sample have been loaded in each well. The exposure 




The experiment shows that MC4100 is capable of exporting hGH into the periplasm 
as expected and in the periplasmic fraction of ∆tat there is no hGH signal. Clones 1 
and 2 do not show any traces of hGH on the western blot and it appears that hGH was 
degraded as only a faint hGH signal is visible in the cytoplasmic fraction of Clone 1 
(Figure 23B). The two A. tumefaciens TatABC clones are not able to export hGH into 
the periplasm when expressed with a TorA signal peptide (Figure 23B). The native 
TorA is still present in the cell. As the wildtype strain is expressing the protein, it is 
likely that the protein in Clone 1 and Clone 2 is expressed but degraded. hGH has been 
in previous work shown to be susceptible to degradation (Browning et al., 2017). 
Comparing Clone 1 and Clone 2, a faint band can be seen in the cytoplasm of Clone 1 
that does not appear in Clone 2. 
The same cells expressing hGH were used to perform the TMAO assay, as previously 
described, to evaluate whether native Tat substrates are expressed during the protein 
expression. 
 
Figure 24: TorA activity during TorA-SP-hGH expression. TorA-SP-hGH was induced 
with 1 mM IPTG and was expressed at 30°C in TMAO containing Luria Broth (LB) 
medium. To show whether native substrate activity is still occuring when expressing a non-
native protein via Tat, we have also taken samples for a TMAO assay throughout protein 
expression. Here shown is a CN-PAGE gel. The gel is a representative of two gels and 10 




Clone 2, which was unable to export hGH to the periplasm (Figure 23B), was still able 
export TorA to the periplasm (Figure 24). In contrast Clone 1, in which a small amount 
of hGH was detected in the cytoplasm (Figure 23B) showed very little periplasmic 
TorA. It is possible that in this strain high level expression of TorA-SP-hGH interfered 
with the export of native TorA. 
 
3.2.5. MC4100 A. tumefaciens TatABC is not capable of exporting single chain 
variable fragments into the periplasm 
To further test the abilities of MC4100 clones containing A. tumefaciens TatABC on 
the chromosome we tested different single chain variable fragments (scFv’s). We used 
an expression plasmid containing the TorA signal peptide linked to a single chain 
antibody variable fragment (TorA-SP-scFv) and expressed the plasmid in the two 
clones. The export was compared with MC4100 wildtype and ∆tat. These constructs 





Figure 25: Expression of scFv(cobra) with the Tat specific signal peptide TorA in the 
new strains. Cells were grown in 50mL LB shake flask cultures at 30˚C. scFv(cobra) (29.5 
kDa, arrowed) was induced with 1 mM IPTG after reaching an OD600 of 0.4 and cells were 
expressed for 3-hours post induction. A shows the Coomassie stained SDS-PAGE gel B 
shows the western blot of the fractions. The western blot was immunoblotted using a C-
terminal anti-his antibody. The gel is a representative of two gels and 10 µL sample have 
been loaded in each well. The exposure time of the western blot is 5.8 seconds. 
 
Comparing the fractions of Clone 1 and Clone 2 on the Coomassie stained SDS-PAGE 
gel shows that the periplasm of Clone 2 has a higher-level cross-contamination with 
cytoplasmic proteins than Clone 1 (Figure 25A). Cytoplasmic contamination of 
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periplasmic samples is indicated by an appearance in the periplasmic fraction of 
multiple high molecular bands, (>55kDa). Comparing the periplasmic fractions in the 
Coomassie stained SDS gel, there are slight difference seen between the different 
strains. MC4100 exports scFv(cobra) into the periplasm as it can be seen due to the 
vast majority of scFv being found in the periplasmic fraction in the western blot. The 
two clones are not able to export TorA-SP-scFv(cobra) into the periplasm as shown in 
Figure 25B. Interestingly, Clone 1 expresses scFv(cobra) but is not exporting it into 
the periplasm while Clone 2 does not show any expression. The protein might also be 
degraded as scFvs are likely to be degraded when they are not exported (Alanen et al., 
2015). 
We furthermore investigated a different scFv called scFv(M) which has been 




Figure 26: Expression of single chain variable fragment (scFv) variant with the Tat 
specific signal peptide TorA in the new strains. Cells were grown in 50mL LB shake 
flask cultures at 30˚C. After reaching an OD600 of 0.4 the plasmid containing scFv(M) (28 
kDa, arrowed) was induced with 1 mM IPTG and was expressed for 3 hours. Cell samples 
were fractionated and immunoblotted. The western blot was immunoblotted using a C-
terminal anti-his antibody. The gel is a representative of two gels and 10 µL sample have 
been loaded in each well. The exposure time of the western blot is 5.8 seconds. 
 
The two clones are also not able to export TorA-SP-scFv(M) into the periplasm 
(Figure 26). Clone 1 appears to express TorA-SP-scFv(M) but the signal is only visible 









3.2.6. MC4100 A. tumefaciens TatABC is not capable of exporting GFP into 
the periplasm 
Furthermore, we investigated whether TorA-SP-GFP can be exported in the new 
strains. GFP has been successfully exported by the Tat pathway in E. coli wildtype 




Figure 27: Expression of TorA-SP-GFP in the new strains compared to MC4100 and 
∆tat. Cells were grown in 50mL LB shake flask cultures at 30˚C. The plasmid containing 
GFP (27 kDa, arrowed) was induced with 1 mM IPTG after reaching an OD600 of 0.4 and 
was expressed for 3-hours. Samples were fractionated. A shows the Coomassie stained 
SDS-PAGE gel B shows the western blot of the fractions. The western blot was 
immunoblotted using a C-terminal anti-his antibody. The gel is a representative of two 
gels and 10 µL sample have been loaded in each well. The exposure time of the 
western blot is 5 seconds. 
 
In Clone 1 TorA-SP-GFP was expressed but was not exported into the periplasm while 
TorA-SP-GFP was not expressed in Clone 2 (Figure 27). However, MC4100 did not 
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express TorA-SP-GFP in this experiment. Therefore, we repeated the expression in 
BL21 DE3 cells to show that the expression of this plasmid is possible. In Figure 28A 




Figure 28: GFP is expressed in BL21 DE3. BL21 DE3 cells containing TorA-SP-GFP 
were expressed in a 50mL LB shake flask culture at 30˚C. The plasmid containing GFP (27 
kDa, arrowed) was induced with 1 mM IPTG and was expressed. A shows the Coomassie 
stained SDS-PAGE gel B shows the western blot. The western blot was immunoblotted 
using a C-terminal anti-his antibody. The gel is a representative of two gels and 10 µL 




3.2.7. MC4100 A. tumefaciens TatABC is not capable of exporting co-
translationally folded proteins 
scFv’s, hGH, and GFP are typically translocated by the E. coli Tat system and are well 
established for testing Tat translocation abilities. None of those proteins was 
translocated by Clone 1 or Clone 2. Therefore, we investigated further proteins, that 
were previously exported by E. coli wildtype Tat. The proteins investigated are co-
translationally folded and their expected sizes are smaller than previously investigated 
proteins. Co-translational folding means that the substrate is folded during protein 
synthesis. Proteins that are folded rapidly are translocated by the Tat system. It is not 
known at what stage of synthesis Tat substrates interact with the Tat complex and 
therefore substrates that are folded co-translationally are an interesting target group. 
The here tested substrates are spectrin R16 (13.4 kDa) and Protein G B1 domain 
(Protein G) (7 kDa). Spectrin R16 is a three-helix bundle protein which is crucial for 
the integrity of plasma membranes(Glyakina et al., 2018). 
Neither Clone 1 nor Clone 2 expressed R16 (Figure 29A and Figure 29B). 
Furthermore, no signal could be achieved in the MC4100 wildtype as seen in Figure 
29B. The original expression of this protein was carried out in BL21 (DE3) cells and 




Figure 29: Expression of TorA-SP-R16 in the new strains compared to MC4100 and 
∆tat. Cells were grown in 50mL LB shake flask cultures at 30˚C. The plasmid containing 
R16 (13.4 kDa, arrowed) was induced with 1 mM IPTG after reaching an OD600 of 0.4 and 
was expressed for 3-hours. Samples were fractionated. A shows the Coomassie stained 
SDS-PAGE gel B shows the western blot of the fractions. The western blot was 
immunoblotted using a C-terminal anti-his antibody. The gel is a representative of two gels 






Figure 30: Expression of TorA-SP-Protein G in the new strains compared to MC4100 
and ∆tat. Cells were grown in 50mL LB shake flask cultures at 30˚C. The plasmid 
containing Protein G (7 kDa, arrowed) was induced with 1 mM IPTG after reaching an 
OD600 of 0.4 and was expressed for 3-hours. Samples were fractionated. A shows the 
Coomassie stained SDS-PAGE gel B shows the western blot of the fractions. The western 
blot was immunoblotted using a C-terminal anti-his antibody. The gel is a representative of 
two gels and 10 µL sample have been loaded in each well. The exposure time of the western 




We furthermore investigated the Protein G domain, which also could not be expressed 
in both clones and in MC4100 (Figure 30A and Figure 30B). The original expression 
Protein G was carried out in BL21 (DE3) cells and expression trials would have 
needed to be repeated in BL21 (DE3) as a positive control which was not possible due 





In this study, we investigated the ability of an alternative tat operon to perform export 
in E. coli cells. This potentially could enable the production of biopharmaceutical 
targets in E. coli that currently require production in mammalian cells due to their 
complex folding structures. We chose the tatABC operon of A. tumefaciens and we 
show that inserting the operon onto the genome can improve the growth pattern of 
∆tat cells. Cells with a non-functional Tat system are lacking the ability to separate 
the cell membrane which is referred to as ‘chaining’. We can show that the non-native 
operon is capable of integrating into the genome and restores cell division. This 
suggests that native Tat proteins can be exported by the foreign Tat operon. This result 
is exciting because so far expression studies on other systems have involved 
expression of plasmid borne tat operons in the E. coli ∆tat strain. We furthermore 
proved by exporting the E. coli native Tat protein TorA into the periplasm that the 
new E. coli MC4100 clones are capable of exporting a Tat native substrate. 
Throughout the course of this study two clones have been created containing the A. 
tumefaciens TatABC sequence on the genome. Both sequences have been confirmed 
by sequencing and Clone 1 has a point mutation which is affecting the 41st amino acid 
mutating a lysine to an arginine. This could be due to point mutations arising during 
the PCR for the GATC sequence or throughout the gene doctoring process. Despite 
the mutation in TatB, Clone 1 is capable of exporting a E. coli native Tat protein TorA. 
Furthermore, TatA of Clone 2 can be immunoblotted using an E. coli TatA specific 
antibody, but Clone 1 cannot. The sequencing shows that both clones have minor point 
mutations in their sequence which could be the reason for the differences in phenotype 
and export. Further research into the differences between Clone 1 and Clone 2, such 
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as transcription levels or membrane integration, could have allowed further insight 
into the expression differences. 
Additionally, we conducted expression trials on both clones. Clone 1 is capable of 
expressing scFv(cobra) but neither Clone 1 nor Clone 2 are able to export scFv(cobra) 
into the periplasm. Further proteins assessed in this study are scFv(M), GFP, hGH, 
R16, and Protein G. None of those proteins was exported into the periplasm. These 
proteins were chosen as they have previously been shown to be exported using the E. 
coli Tat system and are good target proteins to test Tat export (Delisa, Tullman and 
Georgiou, 2003; Browning et al., 2017). However, these proteins are degraded quickly 
and the reason for this is not clear. It could be that some sort of proofreading process 
is involved which degrades the proteins when their export is unsuccessful (Alanen et 
al., 2015; Sutherland et al., 2018). 
The two MC4100 clones containing the tatABC A. tumefaciens operon on the genome 
are capable of exporting E. coli native proteins. However, their proofreading 
mechanisms are more selective than the E. coli native one. None of the substrates 
tested in this study could be exported into the periplasm. A. tumefaciens is mostly 
known for its infectious behaviour towards plants and the translocation of proteins by 
the Tat system of this bacterium has not been researched extensively. It is known that 
the TatA, TatB, and TatC from A. tumefaciens are similarly integrated into the 
cytoplasmic membrane compared to TatABC. Based on the current information, it is 
unclear why the tat operon from A. tumefaciens is more restrictive than the E. coli tat 
operon. 
In summary, Clone 1 shows a point mutation in the TatB region, shows a phenotype 
change (clumping of cells), exports E. coli native Tat protein TorA very well, and 
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TatA is not picked up by an E. coli TatA specific antibody. Clone 2 has the correct 
codon optimised A. tumefaciens TatABC sequence, the filamentous phenotype is 
complemented, the E. coli native Tat protein TorA is exported but at reduced rate 
compared to Clone 1, and TatA is detected by an E. coli TatA specific antibody. It is 
thus not clear why Clone 2 shows no complementation of the phenotype – if anything, 
the correct Tat sequences and clear expression of TatA protein suggest that it should 
be superior to Clone 1. It could be that the gene doctoring process has introduced other 
mutations in the genome, but we have no information about any such additional 
changes. 
In future experiments, the new clones could be further tested about their expression 
ability. Further plasmids for the gene doctoring process were designed and in future 
experiments I would like to insert TatABC from Mesorhizobium loti and TatAAC 
from Synechocystis sp. onto the E. coli genome and investigate their export abilities. 
Furthermore, the proteins investigated in this study showed better expression in BL21 
(DE3) wildtype cells than MC4100. Therefore, in further experiments I would like to 











The production of proteins is essential for every organism. In organisms, expression 
systems are naturally controlled by promoters (Haugen, Ross and Gourse, 2008). 
Those promoters have been used to express recombinant proteins, the tac promoter for 
example is industrially well established for expression in E. coli because it is a strong 
promoter and is easily regulated (Rosano and Ceccarelli, 2014; Öztürk, Ergün and 
Çalık, 2017). The tac promoter is a hybrid promoter derived from the trp and lac 
promoter (de Boer, Comstock and Vasser, 1983). In the past, gene expression of up to 
50% of total cellular protein in E. coli has been achieved (Miroux and Walker, 1996). 
This shows promoters are a powerful tool for biopharmaceutical production. 
Improving promoter strength as well as improving inducibility and tightness of 
regulation can have different benefits. It can improve the quality of the expressed 
protein and it can improve cost efficiency. Optimising the promoter used for 
expression of the target protein allows production of high quantities of recombinant 
protein at low costs. Induction of the tac promoter using IPTG can be costly in large 
processes and hence cheaper alternatives are required. During an induction 
experiment, cells are grown until they reach mid-log phase. Then the cells are induced 
to initiate protein expression. After a process-dependent expression time the cells are 
harvested for protein purification. 
Furthermore, promoters have to be tightly controlled because access levels of target 
protein can induce secretion stress and can cause the protein to go into inclusion bodies 
(Kawe, Horn and Plückthun, 2009). Costs are unfortunately often increased by the 
inducer needed for the promoter. The previously mentioned tac promoter is induced 
by Isopropyl-β-D-thiogalactopyranosid (IPTG), as are others such as the grac 
promoter (Phan, Nguyen and Schumann, 2012). 
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In this study, the aim was to investigate if an alternative promoter, pnarG-CC, could 
provide a cheaper and more effective tool for the biotechnological industry. The narG-
CC promoter has been designed by the Steve Busby laboratory from the University of 
Birmingham and a fusion of the the narG promoter and the CC (-40.5) promoter. A 
schematic presentation of the promoter is shown in Figure 31. Binding sites of NarL 
which is a transacting regulator, the integration host factor (IHF) and a cyclic AMP 
receptor protein (CRP) (Andrew J Darwin and Stewart, 1996; Browning, Butala and 
Busby, 2019) are used in this promoter. IHF is only found in gram-negative bacteria 
and introduces DNA modification that supports DNA interaction in nucleoprotein 
arrays (Goosen and van de Putte, 1995). CRP controls transcription by binding to the 
effector cAMP (Yang et al., 2016). CRP is a strong activator when it is at position -
41.5 upstream of the transcriptional start site. When it is at position -40.5, however, 
CRP is less active and the promoter requires another transcription factor (Rossiter et 
al., 2011, 2015). This support is provided by the regulatory element NarL. 
 
Figure 31: The figure shows a schematic presentation of the narG-CC (-40.5) promoter. 
The location of the binding sites for NarL, IHF and CRP are indicated. The start site of 
transcription is shown by a bent arrow. (Adapted from a presentation given by Douglas 
Browning at the Recombinant Protein Production 10 conference). 
 
Sodium nitrate is easily available even in countries that may have difficulties to 
receive biopharmaceutical supplies. Furthermore, sodium nitrate is a cheaper resource 
than IPTG. As nitrate can be used by E. coli cells during anaerobic conditions, the 
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metabolism of the cells needs to be adapted so that sodium nitrate is not metabolised 
throughout the expression process (Richardson and Watmough, 1999). Further 
challenges a new promoter has to overcome are efficiency and the transcriptional 
activity needs to be tightly controlled (Makrides, 1996; Terpe, 2006). Therefore, we 
aimed to determine whether pnarG-CC can express similar amounts of protein 
compared to more commonly used promoters and how tightly controlled the promoter 
is. Additionally, we investigated whether the promoter allows export of protein into 
the periplasm via the Tat pathway, as well as whether nitrate is continuously available 





4.2.1. pnarG-CC can be used for single induction 
To be an efficient tool for the biotechnology industry the narG-CC promoter has to be 
able to be expressed with a single induction, like the tac promoter. Therefore, it is 
important to ascertain whether the nitrate used for induction is metabolised by the host 
strain. Wildtype E. coli has three pathways involved in nitrate metabolism under 
anaerobic conditions. The strains used in this work have a deletion of the major nitrate 
pathway, the narGHJI operon, and are called N11 and Tn3.1 (Douglas Browning, 
University of Birmingham, unpublished work). N11 is an E. coli K-12 based strain 
which has narG (the major nitrate reductase) knocked out. The strain Tn3.1 has the 
same deletion but is based on E. coli K-12 W3110 TatExpress. Both strains have been 
engineered in the Steve Busby lab using gene doctoring (Lee et al., 2009). 
To determine whether the sodium nitrate would be metabolised by the cells we ran a 
fed-batch fermentation containing E. coli N11. This was to prevent the strain from 
using nitrate to respire under anaerobic conditions. We transformed a plasmid 
expressing GFP driven by the narG-CC promoter into the N11 strain. After induction 
with 20 mM sodium nitrate, time points were taken during the fermentation run and 
we measured the nitrate concentration in the medium over the time course of 38 hours. 
If the nitrate concentration is stable throughout the run, the promoter in combination 
with the strain is feasible for comparison to the tac promoter. 
Sodium nitrate appears to be continuously present in the medium at approximately 20 
mM concentration and continuously induces the narG-CC promoter. The nitrate assay 
proves that a 20 mM nitrate induction is a sufficient amount of inducer for a 38-hour 
fermentation process (Figure 32). Additionally, in the western blots of this 
fermentation run (Figure 35 on page 119) the protein concentration of GFP appears to 
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increase which supports the fact that nitrate is continuously available throughout 
fermentation. 
 
Figure 32: Nitrate and nitrite concentration in the medium of a fed-batch fermentation. 
GFP was expressed using a sodium nitrate inducible promoter (pnarG-CC) in a fed-batch 
fermentation in SM6 medium. 20 mM sodium nitrate was added as inducer after 11 hours 
growth in the fermenter and the nitrate concentration has been measured post-induction 
with a commercial nitrate colorimetric assay as described in 2.8.1 Nitrite/ Nitrate assay kit 
(Sigma Aldrich). Induction is marked by the time point 0 hours. The N11 strain does not 
contain narG, which encodes nitrate reductase, on the genome. 
 
4.2.2. pnarG-CC shows tightly controlled expression in MS and SM6 media 
Ideally the new promoter should be tightly controlled and not express the protein of 
interest before induction. We investigated different media to determine which ones 
allow tight regulation of the promoter. We compared a fermentation medium, SM6, to 
the MS medium used in Birmingham, both described in the Materials and Methods. 
Both media are minimal salt media that contain salts and nitrogen, and glycerol as 
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energy source. A huge benefit of minimal salt media is the reproducibility due to each 
of its components being defined (Kolter, 1951). The main difference between SM6 
and MS media is the amount of glycerol in the media. SM6 medium contains 95 g/L 
glycerol and MS medium contains 4 g/L glycerol. Therefore, the availability of 
glycerol as a carbon source varies strongly. The media also have minor differences in 




Figure 33: Comparison of expression of GFP in SM6 medium to MS medium. GFP (27 
kDa, arrowed) was expressed in 50mL shake flasks cultures at 37˚C. SM6 and MS media 
was used. Samples were taken before induction and 3 hours post-induction and the whole 
extract for analysis was prepared. We investigated both the ptac and the pnarG-CC 
promoters in regard to the tightness of the regulation of expression of GFP in N11 cells. 
Samples were analysed by A Coomassie stained SDS-PAGE gel and B western blot. The 
samples were immunoblotted using an anti-GFP antibody. The gel is a representative of 
three gels and 10 µL sample have been loaded in each well. The exposure time of the 




The MS medium shows tight control of expression compared to SM6 medium. The 
recombinantly expressed GFP induced using nitrate (pnarG-CC) or IPTG (ptac) can 
be clearly seen in the Coomassie stained SDS-PAGE gel as both promoters show high 
levels of expression (Figure 33A). The comparison to ptac expressing GFP is the first 
evidence that the narG-CC promoter expresses high levels of protein in shake flask 
performed. Previous research by the Busby lab in Birmingham focused on comparing 
different narG-CC promoter designs in performance. In SM6 medium the narG-CC 
promoter appears to be slightly leaky, as in Figure 33B a low-level signal in the pre-
induction sample can be seen. The expression in MS medium is tightly controlled. In 
further experiments, we changed the base used to increase the pH of the SM6 medium 
to sodium hydroxide instead of ammonia to investigate whether changes in the media 
lead to tighter expression (Figure 34A and Figure 34B). 
Using SM6 as a medium is preferred, as it is the medium used in fermentation in our 





Figure 34: Comparison of control of expression of GFP from ptac and the narG-CC 
promoters. The protein was expressed in 50mL shake flask cultures using SM6 medium 
containing 10 % sodium hydroxide as a base. The cell line used here is N11 and the cells 
were grown at 37˚C in SM6 and MS media. Samples were taken before induction and 3 
hours post induction and whole cell extract was prepared. Samples were analysed by A 
Coomassie stained SDS-PAGE gel and B western blot of GFP (27 kDa, arrowed) containing 
samples. The samples were immunoblotted using an anti- GFP antibody. The gel is a 
representative of three gels and 10 µL sample have been loaded in each well. The exposure 




The narG-CC promoter was compared to the IPTG induced ptac, which shows slightly 
leaky expression of GFP in the SM6 medium containing 10 % sodium hydroxide 
(Figure 34). Furthermore, the narG-CC promoter seems to be reaching higher levels 
of expression of GFP than ptac. The narG-CC promoter is still slightly leaky (Figure 
34B, signal in the pre-induction sample) even in the SM6 medium variant. The 
medium can influence the transcriptional regulation as seen on the tac promoter. 
pnarG-CC is capable of high-level expression in shake flask in different minimal 
media. The level of expression in shake flask experiments is comparably high as the 
expression of the tac promoter. 
 
4.2.3. Expression of GFP in fed-batch fermentation 
In the next step, we investigated the expression of GFP under control of pnarG-CC 
under fermentation conditions. Fed-batch fermentation provides ideal conditions to 
produce high cell mass which can support expression of metabolites. Figure 35 shows 
that expression of GFP with the narG-CC promoter can be scaled-up from a 50 mL 




Figure 35: GFP increases throughout the fermentation under the control of the narG-
CC promoter. E. coli N11 cells expressing GFP (27 kDa, arrowed) from the narG-CC 
promoter were grown in fed-batch fermentation as described in section 2.4.2 and samples 
were taken prior to the induction. The cells were grown under fed-batch conditions in SM6 
medium with glycerol added at a rate of 0.06 uL/min. Throughout the fermentation and the 
whole cell extract was prepared for immunoblotting. Here shown is the western blot of the 
expression of pnarG-CC GFP in N11 cells in SM6 medium. At an OD600 of 36 the pre-
induction sample was taken, and the cells were induced with 20mM sodium nitrate. As 
negative control N11 cells expressing an empty plasmid were used. The fractions were 
immunoblotted using an anti-GFP antibody. The gel is a representative of one gel and 10 
µL sample have been loaded in each well. The exposure time of the western blot is 3 
seconds. 
 
The experiment shown in Figure 35 was repeated, as the cells were not growing over 
an OD600 of 36. In the next fermentation process, we increased the glycerol feed from 
0.06 µL/min of maximum pump feed to 0.15 µL/min to improve the growth conditions 
and achieved an OD600 of 136 (fermentation in Figure 35 and Figure 37). The GFP is 
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clearly visible in the culture (Figure 36) and the GFP levels could have been quantified 
by fluorescence. However, we were not able to do this due to a lack of time. Cells 
expressing GFP from the tac promoter can show similar levels of GFP expression as 
shown in the following section (4.2.4 pnarG-CC is able to express comparable amount 
of GFP to ptac). Furthermore, induced expression could have been compared to an 
experiment without induction because the nitrate in the media could have meant 
equally strong expression. 
 
Figure 36: Fermentation expressing pnarG-CC GFP. The culture shows a yellow-green 
colour due to the expression of GFP. 
 
The GFP is clearly recognisable in the Coomassie-stained gel as a band at about 27 
kDa Figure 37. In both fermentation processes GFP was expressed pre-induction, 




Figure 37: Coomassie stained SDS-PAGE gel showing the production of GFP from E. 
coli N11 expressing the GFP (27 kDa, arrowed) gene from the nitrate-inducible narG-
CC promoter. The cells were grown under fed-batch conditions in SM6 medium with 
glycerol added at a rate of 0.15 uL/min. The culture was induced after 11h with 20 mM 
sodium nitrate. For this experiment the glycerol feed has been increased from 0.06 µL/min 
of maximum pump feed to 0.15 µL/min. As negative control N11 cells expressing an empty 
plasmid were used. Here shown is the whole cell extract. Samples were analysed by 
Coomassie stained SDS-PAGE gel.  
 
The results presented in Figure 37 were achieved by running the fermenter with SM6 
medium and increasing the feed rate of glycerol from 0.06 µL/min to 0.15 µL/min. 
The increased feed rate shows a higher OD during the GFP production as shown in 
Figure 38. Due to the length of the fermentation process, it was not possible to take 




Figure 38: Growth curve of the fermentation of E. coli N11 with 0.15 uL/min glycerol 
feed rate. The cells were grown under fed-batch conditions in SM6 medium. The cultures 
were induced with 20 mM sodium nitrate. 
 
In the next fed-batch fermentation experiment we used SM6 pH adjusted with 10% 
sodium hydroxide instead of ammonium because of a potential interference of the 




Figure 39: Coomassie stained SDS-PAGE gel and western blot showing the production 
of GFP from E. coli N11 expressing the GFP (27 kDa, arrowed) gene from the nitrate-
inducible narG-CC promoter. The cells were grown under fed-batch conditions in 
modified SM6 medium (NaOH instead of ammonium) with glycerol added at a rate of 0.15 
uL/min. The culture was induced after 11 h with 20 mM sodium nitrate. pH was monitored 
using ammonium and 25% sulfuric acid. Here shown is the whole cell extract of the cells. 
As negative control N11 cells expressing an empty plasmid were used. Samples were 
analysed by A Coomassie stained SDS-PAGE gel and B western blot. The fractions were 
immunoblotted using an anti-GFP antibody. The gel is a representative of one gel and 10 





The expression of GFP in the fed-batch fermentation with modified growth conditions 
(glycerol feed rate from 0.06 µL/min to 0.15 µL/min) was high based on that GFP is 
the most abundant protein in the cells. However, tightly controlled expression could 
not be achieved in the fermenter. In this figure the pre-induction sample shows a high 
level of GFP signal indicating expression prior to induction. Adjusting the pH of the 
SM6 medium with ammonium could have caused the pre-induction. However, as 
ammonium was still used as a feed during the fermentation, it is not possible to 
determine if the ammonium has an influence on the narG-CC promoter Based on the 
tightly controlled expression in shake flask (Figure 33), the experiment should be 
carried out using a different method to adjust the pH. 
We also conducted fermentation experiments with MS medium. During these 
fermentations, the cells did not show any significant growth over the period of 48 
hours. 
 
4.2.4. pnarG-CC is able to express comparable amount of GFP to ptac 
To determine whether the narG-CC promoter can produce similar amounts of GFP to 
the tac promoter, we have compared the production of GFP in the fermentation runs 
in SM6 medium pH adjusted with NH4OH at 0.06 µL/min glycerol feed. When the 
glycerol feed was increased to 0.15 µL/min (Figure 39) the cells grew better, and they 
were producing more GFP than ptac. 
In the first presented fermentation (Figure 35), the pnarG-CC GFP expressing cells 
grew poorly and a final OD600 of 32 was reached. Under the same conditions the cells 
expressing ptac GFP reached an OD600 of 94. The narG-CC GFP expressing cells 
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produced less GFP than ptac expressing cells. This is clearly visible on the Coomassie 






Figure 40: Comparison of GFP production from E. coli N11using the narG-CC 
promoter and the tac promoter. Samples were taken throughout a fed-batch fermentation 
run in SM6 medium and a feed rate of glycerol at 0.06 µL/min. The N11 strain was used 
for fermentation. Cells expressing the tac promoter were induced with 1mM IPTG and cells 
expressing the narG-CC promoter were induced using 20 mM sodium nitrate. The culture 
containing pnarG-CC reached a final OD600 of 32 and the culture containing ptac reached 
an OD600 of 94. A shows the Coomassie stained SDS-PAGE gel B shows the western blot. 
Here, the tac promoter produced more GFP and GFP is visible even on the Coomassie 
stained SDS-PAGE gel, see arrow. The fractions were immunoblotted using an anti-GFP 
antibody. The gel is a representative of one gel and 10 µL sample have been loaded in each 
well. The exposure time of the western blot is 2.2 seconds. 
 
In a fed-batch fermentation with a glycerol feed rate of 0.15 µL/min ptac is not 
exporting as much GFP (shown in Figure 41) as it has in the previous experiment 
(Figure 40) were a glycerol feed rate of 0.06 µL/min was used. The reasons for this 





Figure 41: Comparison of GFP concentration expressed using the narG-CC promoter 
compared to the tac promoter. This experiment used SM6 medium with a glycerol feed 
rate of 0.15 µL/min. Samples were induced with 20mM sodium nitrate (pnarG-CC) and 
1mM IPTG (ptac). Under these conditions the E. coli strain N11 reached an OD600 of 100. 
Here shown is the whole cell extract of the cells. Samples were analysed by A Coomassie 
stained SDS-PAGE gel and B western blot. In this run the narG-CC promoter produced 
more GFP and GFP is visible even on the Coomassie stained SDS-PAGE gel. The fractions 
were immunoblotted using an anti-GFP antibody. The gel is a representative of one gel and 





In summary, the narG-CC promoter was capable of achieving similarly high levels of 
recombinant protein production as the tac promoter, providing the batch culture 
condition are adjusted for the higher consumption of glycerol. However, the high-level 
expression in the pre-induction sample shows that expression is not tightly controlled, 
and further experiments are required to investigate the reason for the leaky expression 
in fed-batch fermentation. 
 
4.2.5. pnarG-CC can express TorA-SP-hGH in shake flask under specific 
conditions 
In the next step, we expressed human growth hormone (hGH), TorA-SP-hGH, via the 
Tat pathway into the periplasm in the Tn3.1 strain which over-expressed Tat 
components and has narG deleted (unpublished work, Douglas Browning, University 
of Birmingham). Periplasmic expression is favourable as it allows easier and cheaper 
downstream processing (Matos et al., 2012) and hGH is a protein of pharmaceutical 
interest that was previously successfully expressed and exported into the periplasm 
(Alanen et al., 2015; Browning et al., 2017). In the experiment shown in Figure 42, 
the cells were grown in LB medium in order to induce the narG-CC promoter. 
Samples were fractionated into the cytoplasmic (C), insoluble(I), and periplasmic (P) 
fractions and immunoblotted. western blots of fractionated samples show that TorA-
SP-hGH is exported to the periplasm (periplasmic signal in Figure 42B). Various 
concentrations of sodium nitrate were tested to establish whether there are differences 
in the expression levels. We can show that hGH does not show any expression before 
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induction and that at levels of 5 mM to 30 mM sodium nitrate TorA-SP-hGH is being 
expressed and efficiently exported into the periplasm. hGH cannot be seen on the 
Coomassie stained SDS-PAGE gel (Figure 42A). However, in the western blot a 
double band can be seen. This is likely caused by gel artefacts as clipping of hGH in 




Figure 42: Inducer concentration has minor impact on TorA-SP-hGH expression using 
the narG-CC promoter. Here expressed is TorA-SP-hGH (21 kDa, arrowed) in the strain 
Tn3.1 in 50mL LB shake flasks cultures at 37˚C. Tn3.1 is a ‘TatExpress’ strain with an 
additional deletion of the major nitrate reductase. Samples were fractionated 3 hours post 
induction. A shows the Coomassie stained SDS-PAGE gel B shows the western blot. The 
fractions were immunoblotted using an anti-hGH antibody. The gel is a representative of 
two gels and 10 µL sample have been loaded in each well. The exposure time of the western 
blots is 2 seconds. 
 
We further conducted an experiment in MS medium with pnarG-CC expressing TorA-
SP-hGH in Tn3.1 in a shake flask. Minimal media are the preferred media for 
fermentation because their components are well defined which allows for a high 
reproducibility. After seeing successful periplasmic expression of TorA-SP-hGH in 
LB medium as shown in Figure 42 we expected to see expression in one of the minimal 
salt media. We chose MS medium for this experiment, as it showed similar expression 
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levels of GFP in SM6 when compared to previous experiments (Figure 33) and is (for 
us unknown reasons) the preferred medium for our collaborators at the University of 
Birmingham. 
A 3-hour induction in MS medium at 30 ºC did not produce enough hGH to be detected 





Figure 43: Expression of TorA-SP-hGH in the Tn3.1 strain did not result in export 
using the pnarG-CC promoter. In A and B Tn3.1 TorA-SP-hGH was expressed using the 
narG-CC and tac promoter. The cells were grown at 30˚C and induced with 1mM IPTG 
(ptac), 5mM and 20mM sodium nitrate (pnarG-CC). There was no detectable hGH in the 
fractions. In C and D Tn3.1 TorA-SP-hGH was expressed using the tac and narG-CC 
promoter. The cells were grown at 25˚C and were induced with 1mM IPTG (ptac), 5mM 
and 20mM sodium nitrate (pnarG-CC). A and C show the Coomassie stained SDS-PAGE 
gel. B and D show the western blot. There was no detectable hGH in the fractions 
(cytoplasmic, C; insoluble, I; periplasmic, P). The fractions were immunoblotted using an 
hGH antibody. The gel is a representative of two gels and 10 µL sample have been loaded 




In Figure 43 we expressed TorA-SP-hGH from the narG-CC promoter at 30˚C and 
25˚C. The data in Figure 42 demonstrates that the pnarG-CC promoter is capable of 
expressing TorA-SP-hGH in LB medium, and that it was exported to the periplasm. 
However, the concentration of hGH expressed in MS medium, with a 3-hour induction 
period, is too low to be detected by the antibody and no export could be detected. 
Lower temperatures can improve protein folding and therefore protein production 
(Weickert et al., 1996). Hence, we conducted the same experiment under lower 
temperature to improve folding of the protein. The same experiment at 25 ºC also 
failed to show any protein (Figure 43B). 
 
4.2.6. TorA-hGH can be expressed in a fermenter 
In the next stage, we attempted to express TorA-SP-hGH from the narG-CC promoter 
in a fed-batch fermentation anticipating some expression of hGH related to the longer 






Figure 44: TorA-SP-hGH expressed in N11 throughout fermentation in SM6 medium 
using pnarG-CC. The cell line N11 containing the pnarG-CC TorA-SP-hGH (21 kDa, 
arrowed) plasmid were grown in a fed-batch fermenter containing SM6. Cell samples were 
taken after the induction with 20 mM sodium nitrate. A shows the Coomassie stained SDS-
PAGE gel B shows the western blot. The fractions were immunoblotted using an anti-hGH 
antibody. The gel is a representative of two gels and 10 µL sample have been loaded in each 
well. The exposure time of the western blots is 2.2 seconds. 
 
In Figure 44 different fractionated samples of a fed-batch fermentation with N11 cells 
are shown. In the Coomassie stained SDS-PAGE gel numerous bands above 55kDa 
are visible in the periplasmic fraction. This is an indicator for cytoplasmic 
contamination of the periplasm during the fractionation protocol. Because of the 
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cytoplasmic contamination in the periplasmic samples in Figure 44 it cannot be shown 
that the hGH was exported to the periplasm by the Tat pathway. It is likely that hGH 
is exported into the periplasm in the sample taken 16 hours post-induction because the 
strongest signal occurs in the periplasmic fraction. However, we cannot say this for 
certain as the cells appear more fragile and a more gentle fractionation procedure is 
required. 
 
E. coli strain Tn3.1 expresses more Tat proteins. We therefore decided to use strain 
Tn3.1 to express TorA-SP-hGH from the narG-CC promoter to determine whether the 
number of Tat translocases in strain N11 was the factor limiting hGH production. 
However, the data (Figure 45) indicate that this was not the case as no was hGH 
detected in any of the cytoplasmic, insoluble, and periplasmic fractions. 
Tn3.1 cannot express pnarG-CC TorA-SP-hGH into the periplasm in a fed-batch 
fermentation process and no hGH could be shown in the cytoplasm and insoluble 




Figure 45: TorA-SP-hGH expressed in Tn3.1 throughout fermentation in SM6 medium 
using the narG-CC promoter. The cell line Tn3.1 containing the pnarG-CC TorA-SP-
hGH plasmid (21 kDa, arrowed) were grown in a fed-batch fermenter containing SM6. Cell 
samples were taken after the induction with 20 mM sodium nitrate and were fractionated. 
A shows the Coomassie stained SDS-PAGE gel B shows the western blot. The fractions 
were immunoblotted using an anti-hGH antibody. The gel is a representative of two gels 





4.2.7. TorA-SP-scFv cannot be exported to the periplasm using pnarG-CC 
To test another protein that is relevant to pharmacology, we used pnarG-CC to express 
TorA-SP-scFv with pnarG-CC at shake flask scale. Whilst TorA-SP-scFv was 
expressed in SM6, it is not exported into the periplasm (Figure 46B) and the protein 
is not visible as an additional protein band on the Coomassie stained SDS-PAGE gel 
(Figure 46A). However, the signal of the sample using the tac promoter is far stronger 
than the signal of any of the pnarG-CC samples. Furthermore, in the western blot in 
Figure 46 there is a double band in the insoluble fraction. This is most likely caused by 





Figure 46: Expression of pnarG-CC TorA-SP-scFv with varying inducer 
concentrations. Expression of TorA-SP-scFv(cobra) (29.5 kDa, arrowed) was conducted 
in N11 in SM6 medium at 30˚C in 50mL shake flask. Both plasmids were expressed for 3 
hours after reaching an OD600 of 0.5. A shows the Coomassie stained SDS-PAGE gel and 
B shows the western blot. The fractions were immunoblotted using a C-terminal anti-his 
antibody. The gel is a representative of two gels and 10 µL sample have been loaded 






The pnarG-CC promoter can be induced with a single dose of the sodium nitrate 
because the concentration of the inducer remains constant throughout growth (Figure 
32). As shown previously, the pnarG-CC promoter leads to similar levels of GFP 
during fed-batch fermentation as when expressed from the ptac promoter when the 
glycerol feed rate is at 0.15 µL/min. However, expression of GFP in fed-batch 
fermentation is not tightly controlled and further experiments would have been 
required to test whether tightly controlled expression can be achieved. In future 
experiments, we could have adjusted the pH with NaOH during the fermentation 
process and additionally check the nitrate levels in the SM6 medium. 
Expression from pnarG-CC can be tightly controlled at shake flask scale in MS 
medium and SM6 variant, but not during fermentation with the same medium. This 
suggest that there is some nitrate in the medium due to the presence of ammonium 
used to adjust the pH of the medium. Furthermore, N11 and Tn3.1 are both strains that 
are lacking the narG genes and the consequences for cell growth and metabolism of 
these deletions are not known. 
Additionally, pnarG-CC expresses similar amounts of GFP as ptac does in minimal 
salt media and is able to express higher amounts of GFP in a variant of SM6 medium. 
We show here that the glycerol feed impacts the ability on the yield and that the growth 
correlates strongly with the quantity of GFP expressed. Depending on the cell density 
reached during a fed-batch fermentation process pnarG-CC could outperform the tac 
promoter. 
pnarG-CC can also be used to express TorA-SP-hGH, which is successfully exported 
to the periplasm in LB in small scale expression experiments. Regulated expression 
has not been achieved in MS medium in shake flask. Additionally, in shake flask 
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experiments in SM6 medium no hGH could be detected in any of the fractions. This 
may be related to the different growth conditions of the cells in different media. 
Furthermore, various amounts of sodium nitrate were tested in shake flask 
experiments to establish whether there are differences in the protein levels (Figure 42). 
We can show that TorA-SP-hGH is not present before induction and appears to be 
tightly controlled compared to GFP and that at levels of 5mM to 30mM sodium nitrate 
TorA-SP-hGH is being expressed into the periplasm (Figure 42). In fed-batch 
fermentation conditions, expression of TorA-SP-hGH was achieved. However, the 
Coomassie stained SDS-PAGE gel showed cytoplasmic contamination in the 
periplasm fraction. Both N11, which is narG deletion strain, and Tn3.1, which is a 
narG deletion strain overexpressing the Tat system, show cytoplasmic contamination 
in the periplasm after the fractionation (Figure 44). 
To determine whether the data was protein specific we analysed the production of 
another industrially relevant protein, namely TorA-SP-scFV. Here we found that 
TorA-SP-scFV was expressed but was not exported to the periplasm (Figure 46). 
Whilst the narG-CC promoter shows good expression for GFP it does not lead to the 
export of TorA-SP-hGH into the periplasm under fermentation conditions without 
cytoplasmic contamination in the periplasmic fraction (Figure 44). However, TorA-
SP-hGH can be exported successfully into the periplasm in LB medium in shake flask 
(Figure 42). 
The narG-CC promoter is good for a strong expression of proteins such as GFP and 
can reduce expression costs due to the low price of its inducer. In further experiments, 
other targets such as superoxidase dismutase (SOD1) and R16, could be tested in 
regard to their periplasmic export. Spectrin R16 is a three-helix bundle protein which 
is crucial for the integrity of plasma membranes (Glyakina et al., 2018) and SOD1 is 
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an antioxidant which catalyses the dismutation of superoxide radicals (Younus, 2018). 
Furthermore, it could be investigated whether the promoter together with other signal 











Poly (ethylene) terephthalate (PET) is the most commonly used plastic worldwide and 
is typically found in many household products, such as drinking bottles, salad 
packaging, shampoo, and window cleaner. PET is a thermoplastic which consists of 
single carbon or heteroatomic chains and is fully recyclable. However, in Europe 52% 
of PET is recycled and, in the U.S., only 31% (PET Resin Association, 2015). 
Considering that in 2017 worldwide 30.3 million tons of PET were produced, this 
shows a need for better recycling procedures (Plastics Insight, 2019). Less than 10% 
of the plastic used worldwide is currently recycled and traces of plastic were found in 
deep sea and other remote areas. Novel ways of recycling this plastic have to be 
established. Enzymatic degradation of plastic with PET-hydrolases, such as FsC from 
Fusarium solani pisi, was studied but the enzymatic activity was low and in incubation 
studies only 5% of PET was degraded after 96 hours (Ronkvist et al., 2009; Groß et 
al., 2017). 
Throughout a 5-year monitoring of bottle recycling yards, a research group found a 
bacterium that is capable of degrading PET to utilise it as a carbon source. In 2016, 
Yoshida et al. published their research showing that the bacterium Ideonella 
sakaiensis is capable of producing an enzyme called PETase (Yoshida et al., 2016). 
The enzyme breaks down PET into intermediate mono (2-hydroxyethyl) terephthalic 
acid (MHET) and in a secondary step MHETase breaks down MHET to two 
monomers (ethylene glycol and terephthalic acid) (Bornscheuer, 2016). PETase 
allows Ideonella sakaiensis to use PET as its major carbon and energy source (Austin 
et al., 2018). MHET is the first intermediate to produce PET and currently has to be 
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synthesized. This is an exciting discovery as the enzymatic activity of PETase is 88-
fold higher than the FsC-hydrolase (Yoshida et al., 2016). 
Although, PETase has only been recently discovered, its structure and function are 
well studied. Structural studies have shown that PETase has a disulphide bond that is 
predicted to be essential for the enzymatic activity and the protein is predicted to be a 
Tat substrate in I. sakaiensis (Fecker et al., 2018; Huang et al., 2018; Liu et al., 2018). 
Therefore, exporting the protein via the Tat pathway would be potential advantageous. 
Previously, PETase was expressed in Bacillus subtilis via the Sec and Tat pathway. 
The most promising expression was shown with the I. sakaiensis native signal peptide 
SPPETase. (Huang et al., 2018) Furthermore, they achieved best expression in a ∆tat 
deletion strain of Bacillus subtilis and the research group reasoned that the Tat 
translocation components have an inhibitory effect on the secretion of PETase when 
fused to the native signal peptide. The PETase signal peptide is predicted to be a Tat 
signal peptide, however it does not have the Tat motif which may lead to a failure to 
transport through the Tat pathway. 
In this study, we aim to investigate whether the plastic-degrading enzyme, PETase, 
can be exported by the Tat pathway in E. coli. PETase is a protein with significant 
industrial interest, which has previously been shown to be difficult to export in an 
active state in high concentrations (Papadopoulou, Hecht and Buller, 2019). Tat-
mediated export could allow export of correctly folded substrate which makes it a 
useful pathway to use for PETase. To achieve Tat export, we have investigated the 
activity of four different signal peptides targeting the Tat pathway. The signal peptides 
used are AmiC, HyaA, TorA, and PhoD*N. Additionally, we have compared protein 
expression of PETase in CyDisCo strains that can generate disulphide bonds in the 
cytoplasm. a general expression plasmid. We aimed to purify the exported protein to 
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do further studies and evaluate the enzymatic activity. Furthermore, we aimed to 




5.2.1. PETase is not expressed at high levels using the TorA signal peptide 
The TorA signal peptide has shown good activity for exporting non-native proteins to 
the periplasm of E. coli, with proteins such as GFP and hGH (Bernhardt and De Boer, 
2003; Alanen et al., 2015). Here, we used the TorA signal peptide to target PETase to 
the Tat pathway using the tac promoter expressing PETase in the pEXTII plasmid. 
Expression studies using the TorA signal peptide were done at 30˚C, 25 ̊ C and at 20˚C 
in shake flask using LB media. In the 25˚C expression experiment samples were taken 
three hours post induction, and after overnight expression (approximately 16 hours 
post-induction) as shown in Figure 47. Samples were fractionated into the cytoplasmic 
(C), insoluble (I), and periplasmic (P) fractions. The TorA signal peptide does not 
appear to support PETase export and no protein could be visualised on the western 





Figure 47: Comparison of the expression of TorA-SP-PETase in E. coli strain BL21 
DE3 TE at different temperatures and different incubation times. PETase (32 kDa, 
arrowed) was expressed of a pEXTII plasmid using the tac promoter in the strain BL21 
DE3 TE in 50 mL shake flasks cultures at different temperatures in LB. Samples were taken 
3 hours and 16 hours post-induction and were separated into fractions. Cells were induced 
with 100 µM IPTG. A shows the Coomassie stained SDS-PAGE gel B shows the western 
blot. Samples were blotted using a C-terminal anti-his antibody. The gel is a representative 
of two gels and 10 µL sample have been loaded in each well. The exposure time of the 




Furthermore, expression at 20˚C was tested. Lower temperatures can improve folding 
and therefore can allow a protein to be expressed if it is degraded (Weickert et al., 
1996). 
 
Figure 48: TorA-SP-PETase does not express at 20˚C. PETase (32 kDa, arrowed) was 
expressed of a pEXTII plasmid using the tac promoter in the strain BL21 DE3 TE in 50 mL 
shake flasks cultures at 20˚C in LB. Samples were taken 16 hours post-induction and were 
separated into fractions. Cells were induced with 100 µM IPTG. A shows the Coomassie 
stained SDS-PAGE gel B shows the western blot. All samples were blotted using a C-
terminal anti-his antibody. The gel is a representative of two gels and 10 µL sample have 




TorA-SP-PETase is also not expressed at 20˚C as the Coomassie stained SDS-PAGE 
gel in Figure 48A and the western blot in Figure 48B show. Due to the lack of 
expression in any of the experiments no further expression experiments were 
conducted using the TorA signal peptide. It appears that the TorA signal peptide is not 
suitable for the substrate and the protein of interest might be degraded immediately. 
 
5.2.2. PETase is successfully expressed using the HyaA signal peptide 
The next signal peptide that was tested for export is HyaA. HyaA is also a Tat specific 
signal peptide. In the first experiment, we compared expression at two different 




Figure 49: The influence of temperature on the production of HyaA-SP-PETase by E. 
coli strain BL21 DE3 TE. PETase (32 kDa, arrowed) was expressed of a pEXTII plasmid 
using the tac promoter in the strain BL21 DE3 TE in 50 mL shake flasks cultures at different 
temperatures in LB. Samples were taken 3 hours post-induction and were separated into 
fractions. Cells were induced with 100 µM IPTG. A shows the Coomassie stained SDS-
PAGE gel B shows the western blot. Samples were blotted using a C-terminal anti-his 
antibody The gel is a representative of two gels and 10 µL sample have been loaded in each 




As shown in Figure 49B, there is new evidence that PETase is successfully exported 
into the periplasm using the signal peptide HyaA. The export shows a higher efficiency 
at 25˚C than at 30˚C and at 25˚C PETase is found in all cell fractions. PETase is 
probably one of the most abundant bands in the periplasm. However, to fully confirm 
this further controls are needed. Additionally, PETase appears the same size in all 
fractions. This could be related to the clipping of the signal peptide or that the protein 
is mature size because it is degraded in the cytoplasm. This has been previously 
observed by Alanen et al. in 2015 (Alanen et al., 2015). 
At 30˚C the his-tagged substrate only shows a weak signal in the periplasmic fraction. 
To show that the export is efficient a Coomassie stained SDS-PAGE gel (Figure 49A) 
has been done. Through a Coomassie stained SDS-PAGE gel it can be shown whether 
the periplasmic fraction is contaminated with cytoplasmic proteins. Numerous bands 
above 55 kDa are a sign of cytoplasmic contamination in the periplasm. Despite the 
low temperature expression, the cells show faint signs of contamination in the 
periplasm on the Coomassie stained SDS-PAGE gel which could be related to lysis 
during the fractionation process or during the expression (Figure 49A). 
In the next step we repeated this experiment at 20˚C to see whether lowering the 




Figure 50: PETase is synthesised at 20˚C in low concentrations using the HyaA signal 
peptide. PETase (32 kDa, arrowed) was expressed of a pEXTII plasmid using the tac 
promoter in the strain BL21 DE3 TE in 50 mL shake flasks cultures at 20˚C in LB. Samples 
were taken 16 hours post-induction and were separated into fractions. Cells were induced 
with 100 µM IPTG. A shows the Coomassie stained SDS-PAGE gel B shows the western 
blot. Also shown here is the TorA-SP-PETase expression which was shown previously. 
Also shown here is the repeat of the TorA-SP-PETase expression shown previously. 
Samples were blotted using a C-terminal anti-his antibody. The gel is a representative of 
two gels and 10 µL sample have been loaded in each well. The exposure time of the western 
blot is 3 seconds. 
 
Expression at 25˚C appears to be optimal. Decreasing the temperature to 20˚C resulted 
in a faint signal in all fractions (Figure 50B) probably due to the lower temperature. A 
longer incubation time could have led to an accumulation of more protein. At 30˚C 
the protein appears to be degraded. Also shown here is the TorA-SP-PETase 
expression which was shown previously in Figure 48. The SDS gel could not be 
repeated as separate gels due to Covid-19 lockdown. Further experiments on this 
signal peptide will be conducted at 25˚C as it results in the highest protein 
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concentration. Additionally, a construct was tested containing PDI and ErV1p 
(CyDisCo components) on the plasmid. Both components when co-expressed with 
PETase support cytoplasmic disulphide bond formation (Matos et al., 2014). PETase 
has a disulphide bond that is predicted to be essential for the enzymatic activity of 
PETase (Fecker et al., 2018; Liu et al., 2018). The CyDisCo components could support 
the cytoplasmic disulphide bond formation and might improve the protein yields. 
 
Figure 51: Expression of HyaA-SP-PETase with CyDisCo components. PETase (32 
kDa, arrowed) was expressed of a pEXTII plasmid using the tac promoter in the strain BL21 
in 50 mL shake flasks cultures at 25˚C in LB. Samples were taken 16 hours post-induction 
and were separated into fractions. Cells were induced with 100 µM IPTG. A shows the 
Coomassie stained SDS-PAGE gel B shows the western blot. Samples were blotted using a 
C-terminal anti-his antibody. The gel is a representative of two gels and 10 µL sample have 




HyaA-SP-PETase with CyDisCo components is successfully expressing PETase as 
shown in Figure 51B. However, the majority of protein appears to be in the insoluble 
fraction. The construct was expressed in BL21 and in a further experiment, expression 
in BL21 DE3 ‘TatExpress’ (TE) is planned. ‘TatExpress’ E. coli strain contains an 
additional promoter to overexpress the tatABCD operon and yields could be increased 
using this strain (Browning et al., 2017). The experiment has previously been 
conducted in BL21 DE3 TE cells, but no export could be confirmed due to high levels 
of cytoplasmic proteins in the periplasmic fraction. The result is not shown here 
because the experiment was not repeated. Therefore, it needs to be repeated to 
investigate if export can be improved or the overexpression of Tat membrane proteins 
and PETase leads to the lysis of the cells. 
As the cells in the previous experiments lysed, we wanted to verify that PETase was 





Figure 52: Synthesis of HyaA-SP-PETase in a MC4100 ∆tat (tatABCDE) and BL21. 
PETase (32 kDa, arrowed) was expressed of a pEXTII plasmid using the tac promoter in 
the strain BL21 in 50 mL shake flasks cultures at 25˚C in LB. Samples were taken 16 hours 
post-induction and were separated into fractions. Cells were induced with 100 µM IPTG. A 
shows the Coomassie stained SDS-PAGE gel B shows the western blot. Samples were 
blotted using a C-terminal anti-his antibody. The gel is a representative of three gels and 10 
µL sample have been loaded in each well. The exposure time of the western blot is 3 
seconds.  
 
In Figure 52A, the periplasmic fraction shows a high cytoplasmic contamination. 
Synthesis of HyaA-SP-PETase causes the cells to fractionate poorly. Interestingly, the 
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export is much more efficient in the ∆tat strain (Figure 52B) suggesting that PETase 
is exported by Sec. 
Furthermore, we can show that the choice of media has an influence on the expression. 
In Figure 53A and B the Coomassie stained SDS-PAGE gel and western blot of a 
shake flask expression of HyaA-SP-PETase in LB and TB media shown. TB medium 
is a phosphate buffered medium which supports growth due to a higher glycerol 




Figure 53: Comparison of expression of HyaA- SP-PETase in ∆tat in different media. 
PETase (32 kDa, arrowed) was expressed in the strain ∆tat in 400 mL shake flasks cultures 
in LB and TB of a pEXTII plasmid using the tac promoter. Samples were taken 16 hours 
post-induction and were separated into fractions. Cells were induced with 100 µM IPTG. 
A shows the Coomassie stained SDS-PAGE gel B shows the western blot. Samples were 
blotted using a C-terminal anti-his antibody. The gel is a representative of three gels and 10 





The western blot in Figure 53B shows that TB medium can facilitate protein 
expression and improves expression compared to LB medium. 
 
5.2.3. PETase could not be purified using a bench Ni-NTA spin column 
In the next step, we aimed to purify the his-tagged protein from ∆tat HyaA-SP-PETase 
periplasmic sample and from all fractions of the BL21 DE3 TE HyaA-SP-PETase 
samples grown at 25˚C, as shown in Figure 49. Here a Ni-NTA spin column kit was 








Figure 54: Bench top purification of PETase containing samples. A and C show the 
Coomassie stained SDS-PAGE gel B and D show the western blot. Samples shown in 
previous images contained PETase in fractions. These samples are shown next to the 
purified sections, however, have not been loaded onto the same SDS-PAGE gel. To purify 
these PETase containing samples, we loaded the samples on a Ni-spin purification column 
and then blotted the different fractions (cytoplasmic, C; insoluble, I; periplasmic, P) with a 
C-terminal anti-his antibody. Samples are separated in the flow through (FT) section, the 
first wash (W1), the second wash (W2), the first elution (E1), and the second elution (E2). 
The size of PETase is 32 kDA. Samples were blotted using a C-terminal anti-his antibody. 
The gels are a representative of one gel and 10 µL sample have been loaded in each well. 
The exposure time of the western blots are 3 seconds. 
 
Throughout the purification process samples are collected from the flow through (FT), 
the two wash steps (W1 and W2), and the elution steps (E1 and E2). Typically, the 
purified protein is expected to be in the elution fractions if it is expressed. Therefore, 
samples have been loaded onto an SDS-PAGE gel separately to analyse whether 
PETase was expressed. However, the protein could not be eluted in any of the fractions 
(Figure 54) and the purification kit used is not suitable for the purification of our 
construct. 
 
5.2.4. PETase is being expressed using the AmiC signal peptide both with and 
without disulphide bond supporting components 
AmiC is a promiscuous signal peptide and can target substrates to the Tat pathway as 
well as the Sec pathway (Tullman-Ercek et al., 2007). Expression studies were done 
using the AmiC signal peptide at 30˚C and at 25˚C. In the 25˚C expression experiment 
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samples were taken three hours post induction, and after overnight expression 






Figure 55: Comparison of expression of AmiC-SP-PETase in BL21 DE3 TE at different 
temperatures. PETase (32 kDa, arrowed) was expressed of a pEXTII plasmid using the 
tac promoter in the strain BL21 in 50 mL shake flasks cultures at different temperatures in 
LB. Samples were taken 3 hours and 16 hours post-induction and were separated into 
fractions. Cells were induced with 100 µM IPTG. A shows the Coomassie stained SDS-
PAGE gel B shows the western blot. Samples were blotted using a C-terminal anti-his 
antibody. The gels are a representative of two gel and 10 µL sample have been loaded in 
each well. The exposure time of the western blots are 3 seconds. 
 
Figure 55B shows that PETase is being expressed using the AmiC signal peptide. 
However, the fractions could not be clearly separated, and the periplasmic fraction 
shows a high amount of proteins above 55 kDa which is a sign of cytoplasmic 
contamination in the periplasm (Figure 55A). The cells appear to be more prone to 




Figure 56: AmiC-SP-PETase is expressed at lower temperatures. PETase (32 kDa, 
arrowed) was expressed of a pEXTII plasmid using the tac promoter in the strain BL21 
DE3 TE in 50 mL shake flasks cultures at 20˚C in LB. Samples were taken 16 hours post-
induction and were separated into fractions. Cells were induced with 100 µM IPTG. A 
shows the Coomassie stained SDS-PAGE gel B shows the western blot. Samples were 
blotted using a C-terminal anti-his antibody. The gels are a representative of two gel and 10 
µL sample have been loaded in each well. The exposure time of the western blots are 3 
seconds. 
 
Further experiments on the AmiC signal peptide will be conducted at 25˚C. 
A construct supporting cytoplasmic disulphide bond formation and containing the 




Figure 57: Expression of HyaA-SP-PETase with CyDisCo components and AmiC-SP-
PETase with CyDisCo components. PETase (32 kDa, arrowed) was expressed of a 
pEXTII plasmid using the tac promoter in the strain BL21 in 50 mL shake flasks cultures 
at 25˚C in LB. Samples were taken 16 hours post-induction and were separated into 
fractions. Cells were induced with 100 µM IPTG. A shows the Coomassie stained SDS-
PAGE gel B shows the western blot. The gels are a representative of two gel and 10 µL 
sample have been loaded in each well. The exposure time of the western blots are 3 seconds. 
 
In Figure 57A and Figure 57B, the expression of AmiC-SP-PETase with CyDisCo 
components is presented. The fractions show that the periplasmic fraction is 
contaminated with cytoplasmic proteins (Figure 57A). 
168 
 
The same experiment was conducted in BL21 DE3 TE cells, but no export could be 
achieved due to extreme lysis (data not shown). Ideally this experiment would have 
been repeated to investigate whether the lysis is related to the synthesis of PETase or 
related to the fractionation process. To investigate, if AmiC-SP-PETase export is Tat 




Figure 58: Expression in ∆tat to determine whether expression is Tat mediated. PETase 
(32 kDa, arrowed) was expressed of a pEXTII plasmid using the tac promoter in the strain 
BL21 and ∆tat in 50 mL shake flasks cultures at 25˚C in LB. Samples were taken 16 hours 
post-induction and were separated into fractions. Cells were induced with 100 µM IPTG. A 
shows the Coomassie stained SDS-PAGE gel B shows the western blot. Focus in this image 
is the AmiC-SP-PETase expression and the blot would need repeating to show only AmiC 
expression. This was not possible to do due to the Covid-19 lockdown. The ∆tat strain does 
not contain tatABCDE and therefore if the protein found in the periplasm in ∆tat it would 
have been expressed via the Sec pathway. Samples were blotted using a C-terminal anti-his 
antibody. The gels are a representative of three gel and 10 µL sample have been loaded in 




Figure 58A shows that the cells expressing HyaA-SP-PETase are showing more 
proteins in the periplasm than the cells expressing AmiC-SP-PETase. Also, no export 
into the periplasm occurs in a ∆tat strain which proves that AmiC leads to a 
translocation of PETase by the Tat pathway (Figure 58B). Using the signal peptide 
HyaA does not lead to export by the Tat pathway and protein is found in the 
periplasmic fraction when expressed in a ∆tat strain (Figure 58B). 
 
5.2.5. PETase cannot be expressed using PhoD*N as a signal peptide in initial 
experiments 
PhoD is a Tat specific signal peptide which is found in Bacillus subtilis. The here used 
signal peptide has a mutation of alanine in position 51 to asparagine. Therefore, it is 
called PhoD*N. 
The cloning of the construct containing the PhoD*N signal peptide was started before 
the Covid-19 lockdown and due to the research laboratory restrictions only a single 
expression trial could be conducted. The here presented data is preliminary and ideally 




Figure 59: Expression of PhoD*N-SP-PETase. PETase (32 kDa, arrowed) was expressed 
of a pEXTII plasmid using the tac promoter in the strains ∆tat, BL21, and BL21 DE3 TE 
in 50 mL shake flasks cultures at 25˚C in LB. Samples were taken 16 hours post-induction 
and were separated into fractions. Cells were induced with 100 µM IPTG. A shows the 
Coomassie stained SDS-PAGE gel B shows the western blot. Samples were blotted using 
a C-terminal anti-his antibody. The gel is a representative of one gel and 10 µL sample have 
been loaded in each well. The exposure time of the western blots are 3 seconds. 
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Figure 59A and Figure 59B show no signs of expression using the signal peptide 
PhoD*N in different cell lines. 
 
Figure 60: Expression of PhoD*N-SP-PETase with CyDisCo components. PETase (32 
kDa, arrowed) was expressed of a pEXTII plasmid using the tac promoter in the strains 
∆tat, BL21, and BL21 DE3 TE in 50 mL shake flasks cultures at 25˚C in LB medium. 
Samples were taken 16 hours post-induction and were separated into fractions. Cells were 
induced with 100 µM IPTG. A shows the Coomassie stained SDS-PAGE gel B shows the 
western blot. Samples were blotted using a C-terminal anti-his antibody. The gel is a 
representative of one gel and 10 µL sample have been loaded in each well. The exposure 




PhoD*N-SP-PETase with CyDisCo does also not show any expression at 25˚C as the 
Coomassie stained SDS-PAGE gel in Figure 60A and the western blot in Figure 60B 
show. 
 
5.2.6. Further experiments that had been planned 
Based on the results achieved before Covid-19 forced the University to close the 
research laboratories, further experiments had been planned. The signal peptides 
HyaA and AmiC were proven to successfully express PETase in the constructs 
containing the CyDisCo components and the constructs without CyDisCo 
components. Therefore, fed-batch experiments are planned to increase the sample 
volume for purification. Fed-batch fermentation was planned on BL21 HyaA-SP-
PETase with CyDisCo, BL21 AmiC-SP-PETase with CyDisCo, BL21 DE3 TE HyaA-
SP-PETase, and BL21 DE3 TE AmiC-SP-PETase. The periplasmic fraction of those 
samples was planned to be purified on a HisTrap column. A goal of this research was 
to investigate whether E. coli can express active PETase and which yields that can be 
achieved. Due to the lockdown, we could not progress to the activity assays which 
would have included incubating PET with the purified protein and analyse the product 




The four signal peptides that were used in this study have previously shown good Tat 
export. In this study, the signal peptides TorA and PhoD*N could not achieve export 
of PETase. However, the signal peptides HyaA and AmiC could achieve promising 
export into the periplasm. When using the AmiC signal peptide the cells appear to 
lyse. We can show that PETase is expressed by the Sec pathway when the signal 
peptide HyaA is used (Figure 52). PETase is not exported in the periplasm when the 
signal peptide AmiC is used (Figure 58) when using a strain that is lacking the Tat 
pathway. 
We could not achieve sufficient expression at 30˚C with HyaA and AmiC. PETase 
was shown to be heat labile at 40˚C and expression at 30˚C might be too close to the 
heat labile point (Huang et al., 2018). If a high concentration of the protein is toxic to 
the cells, expression at lower temperature might beneficiary to reduce cell stress and 
to improve protein expression. Expression at 25˚C achieved the most promising 
export. 
The majority of expression experiments throughout this study, showed some signs of 
cytoplasmic contamination in the periplasmic fraction of the cells. This was 
determined by comparing the amount of proteins above 55 kDa visualised in the 
periplasmic fraction on a Coomassie stained SDS-PAGE gel. I. sakaiensis, which is a 
gram-negative, aerobic bacteria found in samples from a bottle recycling yard in 
Japan, secretes PETase into the extracellular milieu (Huang et al., 2018). However, it 
is interesting that the cells are more affected by stress when the signal peptide HyaA 
was used compared to the signal peptide AmiC. This might be related to the export 
machinery used during the export with the different signal peptides. It appears that 
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cells are prone to cell stress when the Sec system is used when the signal peptide HyaA 
is used for targeting PETase into the periplasm. However, we cannot determine 
whether the lysis occurred during the expression or during the fractionation and it may 
be that the cells expressing HyaA-SP-PETase are frailer and therefore require a more 
gentle fractionation method. 
Comparing export in Figure 49 and in Figure 52 (ideally would be compared on the 
same blot) the ‘TatExpress’ strain appears to improve export of HyaA-SP-PETase. 
Due to the lockdown the samples could not be shown on the same western blot. 
The periplasmic band in the HyaA-SP-PETase expression using ∆tat suggests that 
PETase is exported by the Sec pathway. This experiment would be interesting to repeat 
using the construct HyaA-SP-PETase with CyDisCo to see how the folding of the 
protein affects the export. 
Furthermore, we tried Ni-NTA spin column purification on the PETase samples with 
the HyaA signal peptide and we could not elute the protein. Further purification 
experiments are required optimising the conditions for the elution of the protein. 
The expression of the plasmids additionally containing the CyDisCo components 
shows that the majority of the protein is in the membrane fraction. There is periplasmic 
export and it would be exciting to investigate whether the purified protein of this 
samples is more active than the protein samples that were expressed without the 
CyDisCo components. 
Different research groups have been expressing PETase using different Tat and Sec 
specific signal peptides. Successful expression has been reported in E. coli and 
Bacillus subtilis (Huang et al., 2018; Seo et al., 2019). However, the reported yields 
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are between 3 and 6.2 mg/L. In this study, we could show efficient export of PETase 
using the signal peptide HyaA and AmiC which has not been shown before. 
Furthermore, this is worth pursuing because of the low yields reported in the literature 




6. Final discussion 
 
Many proteins are produced in mammalian cells such as CHO cells. While they are 
able to express complex proteins that require disulphide bond formation, CHO 
cultures are also costly to maintain (Ranade, 2010; Waegeman and Soetaert, 2011). 
Scientists are continuously searching for ways to decrease the costly factors involved 
in industrial protein production. E coli is still a preferred expression host and the 
expression of proteins in E. coli is a crucial part of the landscape of biopharmaceutical 
production systems (Waegeman and Soetaert, 2011; Mohamed N. Baeshen, 2014). 
While wildtype microorganisms are limited in their capabilities to export complex 
proteins containing cofactors or disulphide bonds, microorganisms can be engineered 
to export such proteins (Lee et al., 2009; Thomason et al., 2014). In Gram negative 
bacterial host systems, expression and secretion into the periplasm is preferred 
because the protein is more accessible during downstream processing and purification 
processes. This is a further cost benefit of microorganisms (Quax, 1997). 
The Tat pathway could offer a solution to the expression problem in microorganisms 
as proteins exported by the Tat pathway are exported into the periplasm in a fully 
folded state (Barrett et al., 2003; Panahandeh et al., 2008). Native Tat substrates often 
contain cofactors and require complex folding (Palmer, Sargent and Berks, 2005). 
Furthermore, the Tat pathway has its own inbuilt proofreading mechanism which, 
despite being poorly understood, helps to maintain the quality of the secreted products 
(Robinson and Bolhuis, 2004; Gangl et al., 2015). The proofreading mechanisms 
allows only correctly folded proteins to export into the periplasm. However, it often 
rejects proteins of interest. Overcoming the proofreading mechanism and being able 
to exploit the Tat pathway could enable E. coli to export proteins up to 150 kDa in 
size (Delisa, Tullman and Georgiou, 2003; Palmer and Berks, 2012). 
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In this study, we have investigated different approaches to facilitate cost effective 
protein expression in E. coli. The first investigated approach is genomic engineering 
an alternative tat operon (TatABC A. tumefaciens) into the E. coli genome (Chapter 
3). Furthermore, we expressed proteins with an alternative promoter that is induced 
with sodium nitrate, which is comparatively cheap compared to established inducers 
such as IPTG (Chapter 4) to improve bacterial expression systems. Additionally, we 
tested if Tat signal peptides can enable a protein of major interest (PETase) to be 
expressed and exported in a functional state by the Tat pathway (Chapter 5). 
TatABC A tumefaciens in the E. coli genome can export Tat native proteins and 
does not affect growth or phenotype. 
Each known Tat system exports a variety of native proteins which differs between the 
different Tat systems and organisms the system occurs in. This suggests that the 
proofreading mechanism of the Tat systems may differ as well. Furthermore, it has 
been shown in the past that a non-functional Tat system in E. coli has a severe impact 
on the growth and cell membrane of the cells (Wexler et al., 2000; Lee et al., 2002). 
In this study, we showed that an alternative tat operon expressed on the E. coli genome 
can export E. coli native Tat proteins and does not affect the growth or phenotype 
compared to wildtype cells. Previously, alternative Tat systems were expressed from 
a second plasmid in E. coli and expression and growth has been impacted by the cell 
stress related to a two-plasmid expression (Frain et al., 2017). 
TatABC A. tumefaciens MC4100 mutants are not able to express proteins such 
as hGH, GFP, scFv(cobra), scFv(M), and co-translationally folded proteins (R16 
and Protein G). 
We have shown that A. tumefaciens Tat is capable of exporting TMAO reductase in a 
E. coli ∆tat strain. However, expression of non-native proteins has not been reported 
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(Oates et al., 2003). We show here that tat operon is highly selective in its export of 
proteins and cannot express and export a variety of proteins such as hGH, GFP, single 
chain variable fragments, and co-translationally folded proteins such as R16 and 
Protein G. It does not provide an improvement for the biopharmaceutical production 
of complex proteins so far rejected by the Tat system. 
To better understand the proofreading and rejection mechanisms of the Tat pathway 
further research would need to be done by inserting other tat operons onto the E. coli 
genome and further test the export capabilities. The differences in the tat operons 
could reveal important insight into the proofreading mechanism and provide an 
opportunity to find less selective Tat systems and be able to export complex and large 
proteins into the periplasm. Throughout the course of this study, further gene doctoring 
constructs have been designed and it would be exciting to insert them into the genome 
to investigate their abilities. 
 
A sodium nitrate induced promoter (pnarG-CC) can express high levels of GFP 
comparably to the commonly established ptac promoter (IPTG induced) in shake 
flask and fed-batch fermentation. 
To further decrease costs of protein production in microorganisms we tested a sodium 
nitrate inducible promoter (pnarG-CC). As previously noted, the commonly used 
inducer IPTG is costly and requires storage at -15 to -25˚C which may not be possible 
in countries entering the biopharmaceutical market. The promoter used here is a novel 
promoter system. Here we show that the promoter using sodium nitrate has high 
expression levels when expressing GFP in shake flask and fed-batch fermentation 
experiments. These are promising findings as regulating gene expression in native 
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promoters is challenging and designing new promoters requires complex screening of 
different promoter assemblies (Liu et al., 2019). 
The narG-CC promoter allows expression and secretion of hGH into the 
periplasm but not scFv. 
We aim to express proteins into the periplasm because downstream processing is 
cheaper as the protein is more accessible for purification processes. Therefore, we 
investigated the ability of the promoter to mediate the export proteins into the 
periplasm by the Tat pathway. We showed that hGH is exported into the periplasm. 
However, this study also showed that scFv was not expressed into the periplasm. 
Overall, this promoter shows promising performance for protein expression. 
Based on the findings in this study, future experiments also involve testing a larger 
spectrum of proteins and other signal peptides in combination with the narG-CC 
promoter and investigating its ability to encourage periplasmic export. 
PETase expression is more efficient at 25˚C compared to 30˚C and 20˚C. 
When expressing PETase in E. coli, we found that the temperature that the culture is 
expressed at has a huge impact on the expression efficiency. In previous studies by 
Huang et al. it has been shown that PETase is heat labile at 40˚C and expression at 
lower temperatures is preferred (Huang et al., 2018). We can show here that growth 
at 25˚C shows the best expression compared to growth at 30˚C and 20˚C. Research 
published earlier this year shows that when PETase is expressed in B. subtilis the 
highest enzyme activity obtained when grown at 28˚C (Wang et al., 2020). Further 
research into the activity of the here expressed protein is required to investigate the 
quality of the expressed protein. 
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PETase can be expressed and secreted into the periplasm using the signal peptide 
of HyaA (probably through the Sec pathway) but cells are lysed when using 
AmiC in a Tat system containing cell line. 
Our research interest is directed to proteins from high industrial value such as the 
recently discovered esterase called PETase. This enzyme is capable of degrading 
polymers and has a high enzymatic activity compared to other proteins capable of 
degrading polymers (Ronkvist et al., 2009; Groß et al., 2017). Natively the protein is 
exported by the Tat pathway but despite all efforts expression in industrial preferred 
hosts is challenging (Huang et al., 2018). It previously could not be exported by the 
Tat pathway in studies using Bacillus subtilis. However, it is expressed using a Tat 
signal peptide (Huang et al., 2018). 
We targeted PETase to the Tat pathway using the signal peptides TorA, HyaA, AmiC 
and PhoD*N and could show expression into the periplasm with HyaA. We show that 
signal peptides are a powerful for protein expression, but were not able to show Tat-
specific expression with these signal peptides. However, due to the lockdown, no 
conclusion of the activity and the yield of the protein could be made. 
The protein is exported into the extracellular milieu in I. sakaiensis and possibly could 
be toxic to the cells. Further experiments will need to be conducted to research whether 
the cells are quarantining the protein in lysosomes. 
 
In this study we successfully express proteins in high yields for biopharmaceutical 
production in E. coli variants. We could not disable the Tat rejection mechanism 
through creating TatABC A. tumefaciens MC4100 mutant strains. However, we 
obtained high yields of protein using a novel promoter and we achieve promising 
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expression results using different Tat signal peptides for periplasmic export of a 
complex folded protein. 
Research presented here regarding the enzyme PETase could be continued with fed-
batch fermentation of the plasmids AmiC-SP-PETase with CyDisCo, AmiC-SP-
PETase, HyaA-SP-PETase with CyDisCo, and HyaA-SP-PETase. Furthermore, in 
future experiments the protein needs to be purified and its activity needs to be 
determined. For this, PET could be incubated with the purified protein and the PET 
samples be analysed using scanning electron microscopy (SEM). If the protein is toxic 
to the cells an alternative promoter system could be used such as the RHA promoter 
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Figure 61: Here shown is the alignment of TatABC E. coli (eco) to TatABC A. tumefaciens 




8.2. Base pair and amino acid sequence of codon optimised TatABC A. 
tumefaciens operon used for pDoc-K 















































8.3. Base pair and amino acid sequence of Clone 1, containing the gene 
encoding the tatABC operon of A. tumefaciens  









































8.4. Base pair and amino acid sequence of Clone 2, containing the gene 
encoding the tatABC operon of A. tumefaciens  









































8.5. Alignment of Clone 1 insertion to the A. tumefaciens tatABC operon 
 
 
Figure 62: Here shown is the alignment of the A. tumefaciens tatABC sequence to the 









8.6. Alignment of Clone 2 insertion to the A. tumefaciens tatABC operon 
 
 
Figure 63: Here shown is the alignment of the A. tumefaciens tatABC sequence to the 
inserted sequence in Clone 2. The sequence has been aligned using multalin 
(http://multalin.toulouse.inra.fr/multalin/multalin.html). 
 
